<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Indomethacin for symptomatic patent ductus arteriosus in preterm infants - Evans, P - 2021 | Cochrane Library</title> <meta content="Indomethacin for symptomatic patent ductus arteriosus in preterm infants - Evans, P - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013133.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Indomethacin for symptomatic patent ductus arteriosus in preterm infants - Evans, P - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013133.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013133.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Indomethacin for symptomatic patent ductus arteriosus in preterm infants" name="citation_title"/> <meta content="Peter Evans" name="citation_author"/> <meta content="Children's Hospital of Philadelphia" name="citation_author_institution"/> <meta content="Deirdre O'Reilly" name="citation_author"/> <meta content="Larner College of Medicine at the University of Vermont" name="citation_author_institution"/> <meta content="Jonathan N Flyer" name="citation_author"/> <meta content="Larner College of Medicine at the University of Vermont" name="citation_author_institution"/> <meta content="Roger Soll" name="citation_author"/> <meta content="Larner College of Medicine at the University of Vermont" name="citation_author_institution"/> <meta content="Souvik Mitra" name="citation_author"/> <meta content="Dalhousie University &amp; IWK Health Centre" name="citation_author_institution"/> <meta content="souvik.mitra@iwk.nshealth.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD013133.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/01/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013133.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013133.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013133.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Bronchopulmonary Dysplasia [epidemiology]; Cause of Death; Cyclooxygenase Inhibitors [administration &amp; dosage, adverse effects, *therapeutic use]; Ductus Arteriosus, Patent [*drug therapy, mortality, surgery]; Enterocolitis, Necrotizing [chemically induced]; Gastrointestinal Hemorrhage [chemically induced]; Incidence; Indomethacin [administration &amp; dosage, adverse effects, *therapeutic use]; Infant, Low Birth Weight; Infant, Premature; Ligation [statistics &amp; numerical data]; Oxygen Inhalation Therapy [statistics &amp; numerical data]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic [statistics &amp; numerical data]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013133.pub2&amp;doi=10.1002/14651858.CD013133.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="u3GUW7vS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013133\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013133\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013133.pub2",title:"Indomethacin for symptomatic patent ductus arteriosus in preterm infants",firstPublishedDate:"Jan 15, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=u3GUW7vS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013133.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013133.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013133.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013133.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013133.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013133.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013133.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013133.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013133.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013133.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7357 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013133.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/appendices#CD013133-sec-0117"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/supinfo/CD013133StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/supinfo/CD013133StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Indomethacin for symptomatic patent ductus arteriosus in preterm infants</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information#CD013133-cr-0004">Peter Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information#CD013133-cr-0005">Deirdre O'Reilly</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information#CD013133-cr-0006">Jonathan N Flyer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information#CD013133-cr-0007">Roger Soll</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information#CD013133-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Souvik Mitra</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information/en#CD013133-sec-0132">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 January 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013133.pub2">https://doi.org/10.1002/14651858.CD013133.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013133-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013133-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013133-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013133-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013133-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD013133-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013133-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013133-abs-0001" lang="en"> <section id="CD013133-sec-0001"> <h3 class="title" id="CD013133-sec-0001">Background</h3> <p>Symptomatic patent ductus arteriosus (PDA) is associated with mortality and morbidity in preterm infants. In these infants, prophylactic use of indomethacin, a non‐selective cyclooxygenase inhibitor, has demonstrated short‐term clinical benefits. The effect of indomethacin in preterm infants with a symptomatic PDA remains unexplored. </p> </section> <section id="CD013133-sec-0002"> <h3 class="title" id="CD013133-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of indomethacin (given by any route) compared to placebo or no treatment in reducing mortality and morbidity in preterm infants with a symptomatic PDA. </p> </section> <section id="CD013133-sec-0003"> <h3 class="title" id="CD013133-sec-0003">Search methods</h3> <p>We used the standard search strategy of Cochrane Neonatal to search Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 7), in the Cochrane Library; Ovid MEDLINE(R) and Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Daily and Versions(R); and Cumulative Index to Nursing and Allied Health Literature (CINAHL), on 31 July 2020. We also searched clinical trials databases and the reference lists of retrieved articles for randomized controlled trials (RCTs) and quasi‐RCTs. </p> </section> <section id="CD013133-sec-0004"> <h3 class="title" id="CD013133-sec-0004">Selection criteria</h3> <p>We included RCTs and quasi‐RCTs that compared indomethacin (any dose, any route) versus placebo or no treatment in preterm infants. </p> </section> <section id="CD013133-sec-0005"> <h3 class="title" id="CD013133-sec-0005">Data collection and analysis</h3> <p>We used the standard methods of Cochrane Neonatal, with separate evaluation of trial quality and data extraction by at least two review authors. We used the GRADE approach to assess the certainty of evidence for the following outcomes: failure of PDA closure within one week of administration of the first dose of indomethacin; bronchopulmonary dysplasia (BPD) at 28 days' postnatal age and at 36 weeks' postmenstrual age; proportion of infants requiring surgical ligation or transcatheter occlusion; all‐cause neonatal mortality; necrotizing enterocolitis (NEC) (≥ Bell stage 2); and mucocutaneous or gastrointestinal bleeding. </p> </section> <section id="CD013133-sec-0006"> <h3 class="title" id="CD013133-sec-0006">Main results</h3> <p>We included 14 RCTs (880 preterm infants). Four out of the 14 included studies were judged to have high risk of bias in one or more domains. Indomethacin administration was associated with a large reduction in failure of PDA closure within one week of administration of the first dose (risk ratio (RR) 0.30, 95% confidence interval (CI) 0.23 to 0.38; risk difference (RD) ‐0.52, 95% CI ‐0.58 to ‐0.45; 10 studies, 654 infants; high‐certainty evidence). There may be little to no difference in the incidence of BPD (BPD defined as supplemental oxygen need at 28 days' postnatal age: RR 1.45, 95% CI 0.60 to 3.51; 1 study, 55 infants; low‐certainty evidence; BPD defined as supplemental oxygen need at 36 weeks' postmenstrual age: RR 0.80, 95% CI 0.41 to 1.55; 1 study, 92 infants; low‐certainty evidence) and probably little to no difference in mortality (RR 0.78, 95% CI 0.46 to 1.33; 8 studies, 314 infants; moderate‐certainty evidence) with use of indomethacin for symptomatic PDA. No differences were demonstrated in the need for surgical PDA ligation (RR 0.66, 95% CI 0.33 to 1.29; 7 studies, 275 infants; moderate‐certainty evidence), in NEC (RR 1.27, 95% CI 0.36 to 4.55; 2 studies, 147 infants; low‐certainty evidence), or in mucocutaneous or gastrointestinal bleeding (RR 0.33, 95% CI 0.01 to 7.58; 2 studies, 119 infants; low‐certainty evidence) with use of indomethacin compared to placebo or no treatment. Certainty of evidence for BPD, surgical PDA ligation, NEC, and mucocutaneous or gastrointestinal bleeding was downgraded for very serious or serious imprecision. </p> </section> <section id="CD013133-sec-0007"> <h3 class="title" id="CD013133-sec-0007">Authors' conclusions</h3> <p>High‐certainty evidence shows that indomethacin is effective in closing a symptomatic PDA compared to placebo or no treatment in preterm infants. Evidence is insufficient regarding effects of indomethacin on other clinically relevant outcomes and medication‐related adverse effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013133-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013133-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013133-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013133-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013133-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013133-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013133-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013133-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013133-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD013133-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013133-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013133-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013133-abs-0002" lang="en"> <h3>Indomethacin for treatment of symptomatic patent ductus arteriosus (PDA) in preterm infants </h3> <p><b>Review question</b> </p> <p>We wanted to see how safe and effective indomethacin is when compared with no treatment or placebo (a substance with no therapeutic effect) in treating symptomatic patent ductus arteriosus (PDA) in a preterm infant. </p> <p><b>Background</b> </p> <p>PDA is a common complication among preterm and low birth weight infants. PDA is an open vascular channel between the lungs and the heart, which usually closes shortly after birth. In preterm infants, the PDA remains open and may contribute to life‐threatening complications. We wanted to see if a medicine commonly used to close PDA, indomethacin, was better or worse than no treatment or placebo for preterm infants who were experiencing symptoms from their PDA. </p> <p><b>Study characteristics</b> </p> <p>We searched scientific databases for randomized controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) in preterm (born at less than 37 weeks into pregnancy) or low birth weight (weighing less than 2500 grams) infants with a symptomatic PDA diagnosed by a combination of specific clinical features and/or ultrasound of the heart. Included studies compared indomethacin versus no treatment or placebo. We searched for studies that had been published up to 31 July 2020. </p> <p><b>Key results</b> </p> <p>This review of 14 clinical trials (880 infants) found that indomethacin is very effective in closing a PDA, reducing the risk of PDA being open at one week by 70%, when compared to no treatment or placebo. Of the 14 total studies, eight reported on death, which was not different between groups. Only one study reported on the number of infants needing oxygen at 28 days of life, and only one study reported on the number of infants using oxygen at 36 weeks' postmenstrual age (how many weeks pregnancy plus how long the infant has been alive). Data are not adequate to permit conclusions on these outcomes. Both studies showed no difference between those who received indomethacin or no treatment or placebo. Medication side effects or other adverse effects (such as gut bleeding, kidney injury, and bowel infection/lack of blood flow called necrotizing enterocolitis) were not different between groups. </p> <p><b>Certainty of evidence</b> </p> <p>According to GRADE (a method used to score the certainty of trials supporting each outcome), high‐certainty evidence shows that indomethacin is effective in closing a PDA in a preterm infant with symptoms. However, there is not enough evidence to say if indomethacin helps to reduce death or lung injury. Also, there is not enough evidence to say if indomethacin causes increased harm compared to no treatment or placebo. More studies are needed to see if indomethacin can reduce death or lung injury in infants with symptomatic PDA. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013133-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013133-sec-0112"></div> <h3 class="title" id="CD013133-sec-0113">Implications for practice</h3> <section id="CD013133-sec-0113"> <p>High‐certainty evidence shows that indomethacin is effective in closing a symptomatic patent ductus arteriosus (PDA) in preterm infants compared to placebo or no treatment. Given that we were unable to demonstrate any other clinically important benefit or to confidently rule out any significant adverse effect with this intervention, the decision to use indomethacin for symptomatic PDA will depend on the value that families and neonatal care providers attach to the surrogate outcome of PDA closure. </p> </section> <h3 class="title" id="CD013133-sec-0114">Implications for research</h3> <section id="CD013133-sec-0114"> <p>It is important to acknowledge that most of the trials included in this review were designed to examine whether indomethacin was effective in closing a symptomatic PDA. These trials were not designed or powered to explore whether indomethacin treatment for symptomatic PDA improved clinically relevant outcomes. Hence most trials had a backup treatment option had the PDA remained open following the initial intervention, as evident from the significantly higher rate of open‐label treatment in the placebo or no treatment group. Therefore, if future trials are designed to examine effects of indomethacin treatment on clinical outcomes, then any open‐label treatment should be strictly disallowed before outcome assessment. Furthermore, trials should be powered for outcomes relevant to patients and families such as mortality, necrotizing enterocolitis (NEC), and neurodevelopment rather than short‐term surrogates such as PDA closure (<a href="./references#CD013133-bbs2-0075" title="WebbeJW , DuffyJM , AfonsoE , Al-MuzaffarI , BruntonG , GreenoughA , et al. Core outcomes in neonatology: development of a core outcome set for neonatal research. Archives of Disease in Childhood. Fetal &amp; Neonatal Edition2020;105(4):425-31. [DOI: 10.1136/archdischild-2019-317501] [PMID: 31732683]">Webbe 2020</a>). Finally, with increasing adoption of conservative management even for symptomatic PDA, future trials should focus on enrolling infants at highest risk of PDA‐related morbidity, based on gestational age, degree of hemodynamic significance of the PDA, and other perinatal characteristics (<a href="./references#CD013133-bbs2-0062" title="MitraS , McNamaraPJ . Patent ductus arteriosus – time for a definitive trial. Clinics in Perinatology2020;47(3):617-39. [DOI: 10.1016/j.clp.2020.05.007] [PMID: 32713454]">Mitra 2020</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013133-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013133-sec-0008"></div> <div class="table" id="CD013133-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Indomethacin compared to placebo or control for symptomatic patent ductus arteriosus in preterm infants</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Indomethacin compared to placebo or control for symptomatic patent ductus arteriosus in preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> symptomatic patent ductus arteriosus in preterm infants<br/><b>Setting:</b> neonatal intensive care setting<br/><b>Intervention:</b> indomethacin<br/><b>Comparison:</b> placebo or control </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with indomethacin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure of PDA closure within 1 week of administration of the first dose of indomethacin</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.30<br/>(0.23 to 0.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>654<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>732 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000<br/>(168 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bronchopulmonary dysplasia at 28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/>(0.60 to 3.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>322 per 1000<br/>(133 to 780) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bronchopulmonary dysplasia at 36 weeks' gestation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.41 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000<br/>(128 to 484) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause neonatal mortality before hospital discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.46 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>314<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/>(75 to 217) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants requiring surgical ligation of PDA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.33 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>275<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000<br/>(37 to 146) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NEC (≥ Bell stage 2)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/>(0.36 to 4.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>147<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(19 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mucocutaneous or gastrointestinal bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33</p> <p>(0.01 to 7.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>119<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; NEC: necrotizing enterocolitis; OR: odds ratio; PDA: patent ductus arteriosus; RCT: randomized controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (there are few events in a small sample single RCT, and the CI includes appreciable benefit and harm). </p> <p><sup>b</sup>Downgraded one level for serious imprecision (the CI includes appreciable benefit and harm). </p> <p><sup>c</sup>Downgraded two levels for very serious imprecision (there are few events from two small sample RCTs, and the CI includes appreciable benefit and harm). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013133-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013133-sec-0009"></div> <section id="CD013133-sec-0010"> <h3 class="title" id="CD013133-sec-0010">Description of the condition</h3> <p>Fetal circulation relies on the placenta, as well as on a patent ductus arteriosus (PDA) (<a href="./references#CD013133-bbs2-0060" title="MathewR . Development of the pulmonary circulation: metabolic aspects. In: PolinRA , FoxWW , editors(s). Fetal and Neonatal Physiology. 2nd edition. Philadelphia (PA): WB Saunders, 1998:924-9.">Matthew 1998</a>). The ductus arteriosus connects the main pulmonary artery to the proximal descending aorta, allowing the vast majority of right ventricular output to bypass the pulmonary circulation (<a href="./references#CD013133-bbs2-0033" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>). Shortly after birth, with initiation of breathing and separation of the low‐resistance placenta, functional closure of the ductus arteriosus begins. Physiological mechanisms for closure include increased oxygen tension and decreased circulating prostaglandin (PGE₂) and prostacyclin (PGI₂). This generally occurs within 24 to 72 hours of birth in the term infant (<a href="./references#CD013133-bbs2-0033" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>). However, the ductus arteriosus frequently fails to close in the preterm infant, with an inverse relationship between gestational age and ductal patency (<a href="./references#CD013133-bbs2-0033" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>; <a href="./references#CD013133-bbs2-0049" title="HammermanC . Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clinics in Perinatology1995;22(2):457-79. [PMID: 7671547]">Hammerman 1995</a>). Seventy per cent of infants born before 28 weeks' gestational age have historically received medical or surgical closure of the PDA (<a href="./references#CD013133-bbs2-0033" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>). Infants with respiratory distress syndrome (RDS) (<a href="./references#CD013133-bbs2-0074" title="ThibeaultDW , EmmanouilidesGC , NelsonRJ , LachmanRS , RosengartRM , OhW . Patent ductus arteriosus complicating the respiratory distress syndrome in preterm infants. Journal of Pediatrics1975;86(1):120-6. [DOI: 10.1016/s0022-3476(75)80722-0] [PMID: 122840]">Thibeault 1975</a>), as well as those with perinatal asphyxia (<a href="./references#CD013133-bbs2-0036" title="CottonRB , LindstromDP , StahlmanMT . Early prediction of symptomatic patent ductus arteriosus from perinatal risk factors: a discriminant analysis model. Acta Paediatrica Scandinavica1981;70(5):723-7. [DOI: 10.1111/j.1651-2227.1981.tb05775.x] [PMID: 7324921]">Cotton 1981</a>), are more likely to have a significant PDA present, as are infants who receive large volumes of fluid early in their life (<a href="./references#CD013133-bbs2-0027" title="BellEF , WarburtonD , StonestreetBS , OhW . Effect of fluid administration on the development of symptomatic patent ductus arteriosus and congestive heart failure in premature infants. New England Journal of Medicine1980;302(11):598-604. [DOI: 10.1056/NEJM198003133021103] [PMID: 7351906]">Bell 1980</a>). The likelihood of spontaneous closure of a PDA in infants less than or equal to 1500 grams remains high, reaching 85% in one cohort before discharge (<a href="./references#CD013133-bbs2-0071" title="SemberovaJ , SircJ , MiletinJ , KuceraJ , BerkaI , SebkovaS , et al. Spontaneous closure of patent ductus arteriosus in infants &lt;/=1500 g. Pediatrics2017;140(2):e20164258. [DOI: 10.1542/peds.2016-4258] [PMID: 28701390]">Semberova 2017</a>). </p> <p>Failure of the ductus arteriosus to close in preterm infants is partially related to altered physiological mechanisms, including increased ductal sensitivity to the vasodilatory effects of prostaglandins and nitric oxide (<a href="./references#CD013133-bbs2-0039" title="DiceJE , BhatiaJ . Patent ductus arteriosus: an overview. Journal of Pediatric Pharmacology and Therapeutics2007;12(3):138-46. [DOI: 10.5863/1551-6776-12.3.138] [PMID: 23055849]">Dice 2007</a>). Additionally, tone and muscle fibers are decreased in the ductus of preterm infants compared to term infants (<a href="./references#CD013133-bbs2-0049" title="HammermanC . Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clinics in Perinatology1995;22(2):457-79. [PMID: 7671547]">Hammerman 1995</a>). RDS can further exacerbate these mechanisms, increasing the likelihood of ductal patency (<a href="./references#CD013133-bbs2-0049" title="HammermanC . Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clinics in Perinatology1995;22(2):457-79. [PMID: 7671547]">Hammerman 1995</a>). </p> <p>Although several clinical findings may be noted, none is entirely specific to a hemodynamically significant PDA. Although often associated with a continuous, 'machine‐like' murmur best heard in the left infraclavicular region, a murmur can be purely systolic or absent, particularly in the first few days of life (<a href="./references#CD013133-bbs2-0042" title="EllisonRC , PeckhamGJ , LangP , TalnerNS , LererTJ , LinL , et al. Evaluation of the preterm infant for patent ductus arteriosus. Pediatrics1983;71(3):364-72. [PMID: 6338474]">Ellison 1983</a>). In cases of hemodynamically significant PDA with an absent murmur, the infant often presents with respiratory distress or cardiac enlargement on chest radiograph (<a href="./references#CD013133-bbs2-0048" title="HammermanC , StratesE , ValaitisS . The silent ductus: its precursors and its aftermath. Pediatric Cardiology1986;7(3):121-7. [DOI: 10.1007/BF02424985] [PMID: 3468491]">Hammerman 1986</a>). Other common clinical findings include a hyperdynamic precordial impulse, tachycardia, bounding pulses, widened pulse pressure, worsening respiratory status, and apnea (<a href="./references#CD013133-bbs2-0042" title="EllisonRC , PeckhamGJ , LangP , TalnerNS , LererTJ , LinL , et al. Evaluation of the preterm infant for patent ductus arteriosus. Pediatrics1983;71(3):364-72. [PMID: 6338474]">Ellison 1983</a>). </p> <p>In the late 1970s, it was recognized that preterm infants without clinical findings of a PDA had lower risk for RDS, bronchopulmonary dysplasia (BPD), and death when compared to similar infants with signs or symptoms of PDA (<a href="./references#CD013133-bbs2-0029" title="BrownER . Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus. Journal of Pediatrics1979;95(5 Pt 2):865-6. [DOI: 10.1016/s0022-3476(79)80454-0] [PMID: 490263]">Brown 1979</a>). Both surgical and pharmacological interventions were shown to be possible and potentially beneficial for preterm infants with a significant left‐to‐right ductal shunt (<a href="./references#CD013133-bbs2-0035" title="CottonRB , StahlmanMT , KovarI , CattertonWZ . Medical management of small preterm infants with symptomatic patent ductus arteriosus. Journal of Pediatrics1978;92(3):467-73. [DOI: 10.1016/s0022-3476(78)80451-x] [PMID: 632994]">Cotton 1978</a>; <a href="./references#CD013133-bbs2-0044" title="FriedmanWF , HirschklauMJ , PrintzMP , PitlickPT , KirkpatrickSE . Pharmacologic closure of patent ductus arteriosus in the premature infant. New England Journal of Medicine1976;295(10):526-9. [DOI: 10.1056/NEJM197609022951003] [PMID: 820994]">Friedman 1976</a>; <a href="./references#CD013133-bbs2-0051" title="HeymannMA , RudolphAM , SilvermanNH . Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. New England Journal of Medicine1976;295(10):530-3. [DOI: 10.1056/NEJM197609022951004] [PMID: 950959]">Heymann 1976</a>; <a href="./references#CD013133-bbs2-0057" title="KittermanJA , Edmunds LH Jr, GregoryGA , HeymannMA , TooleyWH , RudolphAM . Patent ducts arteriosus in premature infants. Incidence, relation to pulmonary disease and management. New England Journal of Medicine1972;287(10):473-7. [DOI: 10.1056/NEJM197209072871001] [PMID: 5048708]">Kitterman 1972</a>). Although systolic blood pressure may be sustained despite a left‐to‐right ductal shunt, the drop in diastolic blood pressure and localized vasoconstriction are believed to contribute to the clinical consequences of PDA (<a href="./references#CD013133-bbs2-0033" title="ClymanRI . Ibuprofen and patent ductus arteriosus. New England Journal of Medicine2000;343(10):728-30. [DOI: 10.1056/NEJM200009073431009] [PMID: 10974138]">Clyman 2000</a>). A significant left‐to‐right shunt secondary to the ductus has been associated with complications that include increased rates of BPD (<a href="./references#CD013133-bbs2-0029" title="BrownER . Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus. Journal of Pediatrics1979;95(5 Pt 2):865-6. [DOI: 10.1016/s0022-3476(79)80454-0] [PMID: 490263]">Brown 1979</a>), intraventricular hemorrhage (IVH) (<a href="./references#CD013133-bbs2-0023" title="BallabhP . Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatric Research2010;67(1):1-8. [DOI: 10.1203/PDR.0b013e3181c1b176] [PMID: 19816235]">Ballabh 2010</a>), and necrotizing enterocolitis (NEC) (<a href="./references#CD013133-bbs2-0040" title="DollbergS , LuskyA , ReichmanB . Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. Journal of Pediatric Gastroenterology and Nutrition2005;40(2):184-8. [DOI: 10.1097/00005176-200502000-00019] [PMID: 15699694]">Dollberg 2005</a>), as well as decreased middle cerebral artery blood flow (<a href="./references#CD013133-bbs2-0076" title="WeirFJ , OhlssonA , MyhrTL , FongK , RyanML . A patent ductus arteriosus is associated with reduced middle cerebral artery blood flow velocity. European Journal of Pediatrics1999;158(6):484-7. [DOI: 10.1007/s004310051125] [PMID: 10378397]">Weir 1999</a>), worsening RDS (<a href="./references#CD013133-bbs2-0055" title="JacobJ , GluckL , DiSessaT , EdwardsD , KulovichM , KurlinskiJ , et al. The contribution of PDA in the neonate with severe RDS. Journal of Pediatrics1980;96(1):79-87. [DOI: 10.1016/s0022-3476(80)80336-2] [PMID: 6892514]">Jacob 1980</a>), and death (<a href="./references#CD013133-bbs2-0039" title="DiceJE , BhatiaJ . Patent ductus arteriosus: an overview. Journal of Pediatric Pharmacology and Therapeutics2007;12(3):138-46. [DOI: 10.5863/1551-6776-12.3.138] [PMID: 23055849]">Dice 2007</a>). However, a precise causal link between these associations has not been demonstrated (<a href="./references#CD013133-bbs2-0028" title="BenitzWE . Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?Journal of Perinatology2010;30(4):241-52. [DOI: 10.1038/jp.2010.3] [PMID: 20182439]">Benitz 2010</a>). </p> </section> <section id="CD013133-sec-0011"> <h3 class="title" id="CD013133-sec-0011">Description of the intervention</h3> <p>For a hemodynamically significant PDA that does not spontaneously close, a medical or surgical intervention may be chosen to achieve ductal closure. Procedural interventions include surgical ligation and transcatheter occlusion. Pharmacological agents include cyclooxygenase inhibitors, such as ibuprofen or indomethacin, and acetaminophen (paracetamol), which is a derivative of acetanilide with weak anti‐inflammatory properties. </p> <p>Current data are inconclusive regarding the comparative efficacy of surgery or medical management as initial treatment for a PDA in preterm infants (<a href="./references#CD013133-bbs2-0059" title="MalviyaMN , OhlssonA , ShahSS . Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database of Systematic Reviews2013, Issue 3. Art. No: CD003951. [DOI: 10.1002/14651858.CD003951.pub3]">Malviya 2013</a>). In clinical practice, surgical ligation or occlusion is frequently used following failure of medical management. Surgical ligation of the ductus is associated with reduced mortality, but surviving infants are at increased risk of neurodevelopmental impairment. Studies addressing survival bias and confounding by indication are lacking (<a href="./references#CD013133-bbs2-0077" title="WeiszDE , MoreK , McNamaraPJ , ShahPS . PDA ligation and health outcomes: a meta-analysis. Pediatrics2014;133(4):e1024-46. [DOI: 10.1542/peds.2013-3431] [PMID: 24639268]">Weisz 2014</a>). </p> <p>Cyclooxygenase inhibitors (including indomethacin and ibuprofen) have been used to treat preterm infants with symptomatic PDA following the finding in both observational and randomized controlled trials (RCTs) that indomethacin increases the PDA closure rate (<a href="./references#CD013133-bbs2-0044" title="FriedmanWF , HirschklauMJ , PrintzMP , PitlickPT , KirkpatrickSE . Pharmacologic closure of patent ductus arteriosus in the premature infant. New England Journal of Medicine1976;295(10):526-9. [DOI: 10.1056/NEJM197609022951003] [PMID: 820994]">Friedman 1976</a>; <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0051" title="HeymannMA , RudolphAM , SilvermanNH . Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. New England Journal of Medicine1976;295(10):530-3. [DOI: 10.1056/NEJM197609022951004] [PMID: 950959]">Heymann 1976</a>). Although numerous studies have indicated that prophylactic closure of the ductus with indomethacin reduces the incidence of severe IVH, hemodynamically significant PDA, and surgical ligation, complications of indomethacin therapy have been noted, including increased risk of bleeding and transient renal insufficiency (<a href="./references#CD013133-bbs2-0037" title="DavisJM , Hendricks-MunozKD , HagbergD , ManningJA . The effects of indomethacin on renal function and intracranial hemorrhage in infants with patent ductus arteriosus. Developmental Pharmacology and Therapeutics1990;14(1):15-9. [PMID: 2311476]">Davis 1990</a>; <a href="./references#CD013133-bbs2-0043" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. Art. No: CD000174. [DOI: 10.1002/14651858.CD000174.pub2]">Fowlie 2010</a>; <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0073" title="StavelM , WongJ , CieslakZ , SherlockR , ClaveauM , ShahPS . Effect of prophylactic indomethacin administration and early feeding on spontaneous intestinal perforation in extremely low-birth-weight infants. Journal of Perinatology2017;37(2):188-93. [DOI: 10.1038/jp.2016.196] [PMID: 27763630]">Stavel 2017</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). Several studies report NEC as an adverse outcome of indomethacin treatment (<a href="./references#CD013133-bbs2-0045" title="FujiiAM , BrownE , MirochnickM , O'BrienS , KaufmanG . Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. Journal of Perinatology2002;22(7):535-40. [DOI: 10.1038/sj.jp.7210795] [PMID: 12368968]">Fujii 2002</a>; <a href="./references#CD013133-bbs2-0047" title="GrosfeldJL , ChaetM , MolinariF , EngleW , EngumSA , WestKW , et al. Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Annals of Surgery1996;224(3):350-5; discussion 355-7. [DOI: 10.1097/00000658-199609000-00011] [PMID: 8813263]">Grosfeld 1996</a>). However, this association was not found in a systematic review of prophylactic intravenous indomethacin (<a href="./references#CD013133-bbs2-0043" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. Art. No: CD000174. [DOI: 10.1002/14651858.CD000174.pub2]">Fowlie 2010</a>). Systematic reviews have indicated that ibuprofen may offer similar efficacy to indomethacin, with lower rates of transient renal insufficiency and NEC, although optimal dosing, duration, and timing of both therapies are uncertain (<a href="./references#CD013133-bbs2-0066" title="NooriS , SeriI . Treatment of the patent ductus arteriosus: when, how, and for how long?Journal of Pediatrics2009;155(6):774-6. [DOI: 10.1016/j.jpeds.2009.07.053] [PMID: 19914428]">Noori 2009</a>; <a href="./references#CD013133-bbs2-0067" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020</a>). </p> <p>Regarding cyclooxygenase inhibitors, several approaches have been taken for PDA treatment, including prophylactic medical therapy within the first 24 hours of life for at‐risk infants (<a href="./references#CD013133-bbs2-0043" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. Art. No: CD000174. [DOI: 10.1002/14651858.CD000174.pub2]">Fowlie 2010</a>; <a href="./references#CD013133-bbs2-0067" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020</a>), treatment following PDA diagnosis, and symptomatic treatment based on clinical and/or echocardiographic criteria to define hemodynamic significance (<a href="./references#CD013133-bbs2-0032" title="ClymanRI . Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. Journal of Pediatrics1996;128(5 Pt 1):601-7. [DOI: 10.1016/s0022-3476(96)80123-5] [PMID: 8627430]">Clyman 1996</a>). </p> <p>This Cochrane Review will evaluate treatment of symptomatic PDA with indomethacin in the preterm infant. A previously published review has evaluated the role of ibuprofen in PDA treatment (<a href="./references#CD013133-bbs2-0067" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020</a>). </p> </section> <section id="CD013133-sec-0012"> <h3 class="title" id="CD013133-sec-0012">How the intervention might work</h3> <p>Prostaglandins play a key role in maintaining ductal muscle relaxation (<a href="./references#CD013133-bbs2-0031" title="ClymanRI , HeymannMA , RudolphAM . Ductus arteriosus responses to prostaglandin E1 at high and low oxygen concentrations. Prostaglandins1977;13(2):219-23. [DOI: 10.1016/0090-6980(77)90003-x] [PMID: 847229]">Clyman 1977</a>). Indomethacin is a non‐selective cyclooxygenase inhibitor that prevents the enzymatic process leading to production of prostaglandins. Inhibition of prostaglandin production results in arteriolar vasoconstriction, which aids ductal closure. Prophylactic treatment aims to achieve ductal closure before development of significant left‐to‐right shunting and the clinical consequences of hemodynamic instability. PDA closure rates with prophylactic use of ibuprofen and indomethacin approach 58% and 57%, respectively (<a href="./references#CD013133-bbs2-0043" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. Art. No: CD000174. [DOI: 10.1002/14651858.CD000174.pub2]">Fowlie 2010</a>; <a href="./references#CD013133-bbs2-0067" title="OhlssonA , WaliaR , ShahSS . Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database of Systematic Reviews2020, Issue 2. Art. No: CD003481. [DOI: 10.1002/14651858.CD003481.pub8]">Ohlsson 2020</a>). However, exposure to these drugs has revealed potential side effects and unclear benefits (<a href="./references#CD013133-bbs2-0028" title="BenitzWE . Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?Journal of Perinatology2010;30(4):241-52. [DOI: 10.1038/jp.2010.3] [PMID: 20182439]">Benitz 2010</a>). Although benefits are associated with indomethacin use, treatment with indomethacin may reduce perfusion to certain organs. This includes reduced cerebral blood flow, which may oppose neurodevelopmental outcomes associated with decreased IVH (<a href="./references#CD013133-bbs2-0041" title="EdwardsAD , WyattJS , RichardsonC , PotterA , CopeM , DelpyDT , et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet1990;335(8704):1491-5. [DOI: 10.1016/0140-6736(90)93030-s] [PMID: 1972434]">Edwards 1990</a>), decreased intestinal perfusion potentially increasing the rate of NEC (<a href="./references#CD013133-bbs2-0034" title="CoombsRC , MorganME , DurbinGM , BoothIW , McNeishAS . Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Archives of Disease in Childhood1990;65(10 Spec No):1067-71. [DOI: 10.1136/adc.65.10_spec_no.1067] [PMID: 2241229]">Coombs 1990</a>), and decreased renal perfusion (<a href="./references#CD013133-bbs2-0030" title="CifuentesRF , OlleyPM , BalfeJW , RaddeIC , SoldinSJ . Indomethacin and renal function in premature infants with persistent patent ductus arteriosus. Journal of Pediatrics1979;95(4):583-7. [DOI: 10.1016/s0022-3476(79)80775-1] [PMID: 480039]">Cifuentes 1979</a>). Indomethacin may also lead to bleeding via inhibition of platelet function (<a href="./references#CD013133-bbs2-0044" title="FriedmanWF , HirschklauMJ , PrintzMP , PitlickPT , KirkpatrickSE . Pharmacologic closure of patent ductus arteriosus in the premature infant. New England Journal of Medicine1976;295(10):526-9. [DOI: 10.1056/NEJM197609022951003] [PMID: 820994]">Friedman 1976</a>). Rather than medically treating all preterm infants at risk or with trivial symptoms attributed to a PDA, targeting treatment only to infants with hemodynamically significant PDA (by clinical and/or echocardiographic/Doppler criteria) may improve the risk‐to‐benefit ratio and limit known adverse exposure to those with the greatest potential to benefit from therapy. </p> </section> <section id="CD013133-sec-0013"> <h3 class="title" id="CD013133-sec-0013">Why it is important to do this review</h3> <p>A Cochrane Review on prophylactic use of indomethacin for medical treatment of PDA in the preterm infant examined studies of asymptomatic preterm infants with PDA and reported only short‐term benefit, with no benefit or harm for long‐term neurodevelopment identified (<a href="./references#CD013133-bbs2-0043" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. Art. No: CD000174. [DOI: 10.1002/14651858.CD000174.pub2]">Fowlie 2010</a>). Benefit may be increased relative to adverse consequences for treatment of symptomatic preterm infants with PDA when compared to prophylactic use. For this Cochrane Review, we will include only studies of indomethacin for preterm infants with a symptomatic PDA. </p> <p>A Cochrane Review assessed the duration of indomethacin therapy for PDA treatment in preterm infants (<a href="./references#CD013133-bbs2-0050" title="HerreraC , HolbertonJ , DavisP . Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database of Systematic Reviews2007, Issue 2. Art. No: CD003480. [DOI: 10.1002/14651858.CD003480.pub3]">Herrera 2007</a>). A prolonged course of indomethacin did not seem to significantly impact clinical outcomes. For this Cochrane Review, we will not assess duration of therapy but will examine differences in dosing. </p> <p>A non‐Cochrane review by Nehgme and colleagues assessed six small randomized trials of intravenous indomethacin for symptomatic PDA (<a href="./references#CD013133-bbs2-0065" title="NehgmeRA , O'ConnorTZ , ListerG , BrackenMB . Patent ductus arteriosus. In: SinclairJC , BrackenMB , editors(s). Effective Care of the Newborn Infant. Oxford: Oxford University Press, 1992:281-324.">Nehgme 1992</a>). The meta‐analysis suggests that indomethacin significantly increased rates of PDA closure, without differences in mortality, IVH, NEC, or chronic lung disease (<a href="./references#CD013133-bbs2-0065" title="NehgmeRA , O'ConnorTZ , ListerG , BrackenMB . Patent ductus arteriosus. In: SinclairJC , BrackenMB , editors(s). Effective Care of the Newborn Infant. Oxford: Oxford University Press, 1992:281-324.">Nehgme 1992</a>). In this Cochrane Review, we will perform an updated examination of the literature. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013133-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013133-sec-0014"></div> <p>To determine the effectiveness and safety of indomethacin (given by any route) compared to placebo or no treatment in reducing mortality and morbidity in preterm infants with a symptomatic patent ductus arteriosus (PDA). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013133-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013133-sec-0015"></div> <section id="CD013133-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013133-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all published and unpublished RCTs, quasi‐RCTs, and cluster‐RCTs, and randomized cross‐over trials. Both superiority trials and non‐inferiority trials were eligible for inclusion. </p> </section> <section id="CD013133-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included preterm infants born at less than 37 weeks' gestation and low birth weight infants (&lt; 2500 grams) treated for symptomatic PDA enrolled within the first 28 days of life. </p> <p>Symptomatic PDA was defined by clinical and/or echocardiographic criteria. Clinical criteria included one or more of a characteristic heart murmur, hyperdynamic precordial impulse, tachycardia, bounding pulses, widened pulse pressure, or worsening respiratory status (<a href="./references#CD013133-bbs2-0038" title="DavisP , Turner-GomesS , CunninghamK , WayC , RobertsR , SchmidtB . Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Archives of Pediatrics &amp; Adolescent Medicine1995;149(10):1136-41. [DOI: 10.1001/archpedi.1995.02170230090013] [PMID: 7550818]">Davis 1995</a>). Echocardiographic criteria included one or more of a transductal diameter greater than 1.5 mm, left atrial aortic root ratio (LA:Ao) greater than 1.3, a left‐to‐right shunt, and “disturbed diastolic flow in the main pulmonary artery with diastolic backflow in the aorta immediately below the ductus arteriosus and forward flow above the ductal insertion” (<a href="./references#CD013133-bbs2-0058" title="LagoP , BettiolT , SalvadoriS , PitassiI , VianelloA , ChiandettiL , et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. European Journal of Pediatrics2002;161(4):202-7. [DOI: 10.1007/s00431-002-0915-y] [PMID: 12014386]">Lago 2002</a>). </p> <p>We excluded infants with other known congenital heart disease and infants who received prior treatment with a cyclooxygenase inhibitor (indomethacin, ibuprofen). </p> </section> <section id="CD013133-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Indomethacin (any dose, any route) versus placebo or no treatment.</p> </section> <section id="CD013133-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD013133-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013133-list-0001"> <li> <p>Failure of PDA closure within one week of administration of the first dose of indomethacin</p> </li> <li> <p>Bronchopulmonary dysplasia (defined as supplemental oxygen need at 28 days' postnatal age (<a href="./references#CD013133-bbs2-0024" title="BancalariE , AbdenourGE , FellerR , GannonJ . Bronchopulmonary dysplasia: clinical presentation. Journal of Pediatrics1979;95(5 Pt 2):819-23. [DOI: 10.1016/s0022-3476(79)80442-4] [PMID: 385815]">Bancalari 1979</a>) or supplemental oxygen at 36 weeks' postmenstrual age with or without compatible clinical and radiographic findings (<a href="./references#CD013133-bbs2-0072" title="ShennanAT , DunnMS , OhlssonA , LennoxK , HoskinsEM . Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics1988;82(4):527-32. [PMID: 3174313]">Shennan 1988</a>)) </p> </li> <li> <p>All‐cause neonatal mortality at 28 days and before hospital discharge</p> </li> </ol> </p> </section> <section id="CD013133-sec-0022"> <h5 class="title">Secondary outcomes</h5> <section id="CD013133-sec-0023"> <h6 class="title">PDA‐related outcomes</h6> <p> <ol id="CD013133-list-0002"> <li> <p>Proportion of infants receiving rescue medical treatment (repeated cyclooxygenase or paracetamol/acetaminophen dosing, or both). This outcome was revised post‐hoc to include any 'open‐label' treatment and was defined as any cyclooxygenase treatment provided after the initial assigned treatment </p> </li> <li> <p>Proportion of infants requiring surgical ligation or transcatheter occlusion</p> </li> </ol> </p> </section> <section id="CD013133-sec-0024"> <h6 class="title">Other outcomes</h6> <p> <ol id="CD013133-list-0003"> <li> <p>Pneumothorax</p> </li> <li> <p>Pulmonary hemorrhage</p> </li> <li> <p>Late‐onset bacterial sepsis</p> </li> <li> <p>Necrotizing enterocolitis (NEC) (≥ Bell stage 2) (<a href="./references#CD013133-bbs2-0026" title="BellMJ , TernbergJL , FeiginRD , KeatingJP , MarshallR , BartonL , et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery1978;187(1):1-7. [DOI: 10.1097/00000658-197801000-00001] [PMID: 413500]">Bell 1978</a>) </p> </li> <li> <p>IVH (intraventricular hemorrhage) (any grade) (<a href="./references#CD013133-bbs2-0068" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529-34. [DOI: 10.1016/s0022-3476(78)80282-0] [PMID: 305471]">Papile 1978</a>) </p> </li> <li> <p>Severe IVH (grade III to IV) (<a href="./references#CD013133-bbs2-0068" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529-34. [DOI: 10.1016/s0022-3476(78)80282-0] [PMID: 305471]">Papile 1978</a>) </p> </li> <li> <p>Periventricular leukomalacia</p> </li> <li> <p>Retinopathy of prematurity (ROP) (any stage) (<a href="./references#CD013133-bbs2-0054" title="International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Archives of Ophthalmology2005;123(7):991-9. [DOI: 10.1001/archopht.123.7.991] [PMID: 16009843]">ICROP 2005</a>) </p> </li> <li> <p>Severe retinopathy of prematurity (severe ROP) (≥ stage III)</p> </li> <li> <p>Surgery for severe ROP (added post hoc)</p> </li> <li> <p>Infant mortality (first year of life)</p> </li> <li> <p>Use of inotropic agents</p> </li> <li> <p>Duration of assisted ventilation (days)</p> </li> <li> <p>Duration of oxygen dependence (days to last discontinuation of any supplemental oxygen)</p> </li> <li> <p>Duration of hospital stay (days)</p> </li> <li> <p>Time to full enteral feeds (days)</p> </li> <li> <p>Cerebral palsy at approximately 2 years' corrected age (as defined by study authors)</p> </li> <li> <p>Neurodevelopmental outcome at approximately 2 years' corrected age (acceptable range 18 months to 28 months) including cerebral palsy, delayed neurodevelopment (Bayley Scales of Infant Development Mental Developmental Index &lt; 70) (<a href="./references#CD013133-bbs2-0025" title="BayleyN . Bayley Scales of Infant and Toddler Development: Administration Manual. Third edition. San Antonio, TX: Harcourt, 2006.">Bayley 2006</a>), legal blindness (&lt; 20/200 visual acuity), and hearing deficit (aided or &lt; 60 decibels on audiometric testing). The composite outcome 'neurodevelopmental impairment' was defined as having any one of the aforementioned deficits </p> </li> </ol> </p> </section> <section id="CD013133-sec-0025"> <h6 class="title">Safety outcomes (harms reported within one week of completion of the intervention)</h6> <p> <ol id="CD013133-list-0004"> <li> <p>Intestinal perforation</p> </li> <li> <p>Renal function</p> <ol id="CD013133-list-0005"> <li> <p>Oliguria (&lt; 1 mL/kg/hour)</p> </li> <li> <p>Serum/plasma creatinine (µmol/L) levels during treatment</p> </li> <li> <p>Serum/plasma creatinine (µmol/L) after treatment</p> </li> <li> <p>Post‐hoc: creatinine &gt; 150 micromole during treatment (post‐hoc)</p> </li> </ol> </li> <li> <p>Hemostasis</p> <ol id="CD013133-list-0006"> <li> <p>Mucocutaneous or gastrointestinal bleeding</p> </li> <li> <p>Platelet count (&lt; 50,000 platelets/µL blood)</p> </li> </ol> </li> <li> <p>Pulmonary hypertension (diagnosed by echocardiographic or Doppler criteria)</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD013133-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <p>We used criteria and standard methods of Cochrane and Cochrane Neonatal (see <a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">the Cochrane Neonatal search strategy for specialized register</a>). We searched for errata or retractions from included studies published in full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>), and, if noted, we reported the date this was done. </p> <section id="CD013133-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive search including Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 7), in the Cochrane Library; Ovid MEDLINE(R) and Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Daily and Versions(R) (1946 to 31 July 2020); and Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1981 to 31 July 2020). We included the search strategies for each database in <a href="./appendices#CD013133-sec-0118">Appendix 1</a>. We did not apply language restrictions. </p> <p>We searched clinical trial registries for ongoing and recently completed trials. We searched the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>), as well as the US National Library of Medicine ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>), via Cochrane CENTRAL. Additionally, we searched the <a href="http://www.isrctn.com/" target="_blank">ISCRTN Registry</a> (i.e. International Standard Randomized Controlled Trials Number) for any unique trials not found through the Cochrane CENTRAL search. </p> </section> <section id="CD013133-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We also searched the reference lists of any articles selected for inclusion in this review to identify additional relevant articles. </p> </section> </section> <section id="CD013133-sec-0029"> <h3 class="title" id="CD013133-sec-0029">Data collection and analysis</h3> <section id="CD013133-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Working in pairs, review authors independently screened search results by title and abstract for studies that potentially met the inclusion criteria. We obtained the full text of any articles that were potentially eligible, and at least two review authors independently performed full‐text assessments. We resolved any disagreements by discussion between the review author team. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD013133-bbs2-0064" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12. [DOI: 10.1016/j.jclinepi.2009.06.005] [PMID: 19631508]">Moher 2009</a>), and we listed in a <a href="./references#CD013133-sec-0139" title="">Characteristics of excluded studies</a> table all studies excluded after full‐text assessment. </p> </section> <section id="CD013133-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>At least two review authors (of PE, JF, DO, and SM) extracted, assessed, and coded all data for each study, using a form designed specifically for this review. We replaced any standard error of the mean by the corresponding standard deviation. We resolved any disagreements by discussion. For each study, one review author (PE) entered extracted data into Review Manager 5 (RevMan 5) (<a href="./references#CD013133-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>); a second review author (SM) checked data entry. If there was a conflict regarding interpretation of data, another review author (RS) was brought in to adjudicate. All review authors assessed the protocol, analysis, and draft manuscript. </p> <p>We collected information regarding the method of randomization, blinding, drug intervention, stratification, and whether the trial was single or multi‐center for each included study. We noted information regarding trial participants including gestational age criteria, birth weight criteria, and other inclusion or exclusion criteria. We analyzed the information on clinical outcomes of the primary and secondary outcomes. </p> </section> <section id="CD013133-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (PE and SM) independently assessed risk of bias (low, high, or unclear) of all included trials using the Cochrane ‘Risk of bias’ tool for the following domains (<a href="./references#CD013133-bbs2-0052" title="HigginsJP , AltmanDG , SterneJA , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p> <ol id="CD013133-list-0007"> <li> <p>Sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Any other bias.</p> </li> </ol> </p> <p>We resolved any disagreements by discussion or by consultation with a third review author. See <a href="./appendices#CD013133-sec-0122">Appendix 2</a> for a more detailed description of risk of bias for each domain. </p> </section> <section id="CD013133-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We performed statistical analyses using RevMan 5 (<a href="./references#CD013133-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We analyzed categorical data using the risk ratio (RR) and the risk difference (RD). For statistically significant outcomes, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH). We analyzed continuous data using the mean difference (MD) and the standardized mean difference (SMD). We reported the 95% confidence interval (CI) for all estimates. </p> </section> <section id="CD013133-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual infant. We considered an infant only once in an analysis. We excluded infants with multiple enrollments unless we could obtain data from the report or the investigators related to the first episode of randomization. If we could not separate data from the first randomization, we excluded the study, as we were not be able to address unit of analysis issues that arise from multiple enrollments of the same infant. </p> <p>We conducted intention‐to‐treat analyses.</p> <p>We intended to use the participating neonatal unit or section of a neonatal unit as the unit of analysis in cluster‐randomized trials. We planned to analyze these using an estimate of the intracluster correlation coefficient derived from the trial (if possible) or from another source, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013133-bbs2-0053" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). </p> <p>If we identified both cluster‐RCTs and individual RCTs, we planned to combine results from both only if there was little heterogeneity between study designs, and if the interaction between the effect of an intervention and the choice of a randomization unit was considered unlikely. We identified no cluster trials in our review. </p> </section> <section id="CD013133-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain data from the primary author if published data provided inadequate information for the review. </p> </section> <section id="CD013133-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We estimated treatment effects of individual trials and examined heterogeneity among trials by inspecting the forest plots and quantifying the impact of heterogeneity using the I² statistic. We assessed the degree of heterogeneity as: </p> <p> <ol id="CD013133-list-0008"> <li> <p>&lt; 25% = no heterogeneity;</p> </li> <li> <p>25% to 49% = low heterogeneity;</p> </li> <li> <p>50% to 75% = moderate heterogeneity; and</p> </li> <li> <p>&gt; 75% = substantial heterogeneity.</p> </li> </ol> </p> <p>If statistical heterogeneity was present (I² statistic value &gt; 50%), we explored possible causes (e.g. differences in study quality, participants, intervention regimens, or outcome assessments). </p> </section> <section id="CD013133-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>If we suspected reporting bias, we contacted trial investigators to request missing outcome data. If this was not possible, and we considered the missing data to have introduced serious bias, we planned to explore the impact of including such trials in the overall assessment of results by conducting a sensitivity analysis. </p> </section> <section id="CD013133-sec-0038"> <h4 class="title">Data synthesis</h4> <p>In studies judged to be sufficiently similar, we performed meta‐analysis using RevMan 5 (<a href="./references#CD013133-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). For categorical outcomes, we calculated typical estimates of RR and RD, each with its 95% CI; and for continuous outcomes, we determined the MD or a summary estimate for the SMD, each with its 95% CI. We used a fixed‐effect model for meta‐analysis. If we considered meta‐analysis to be inappropriate, we analyzed and interpreted individual trials separately. </p> </section> <section id="CD013133-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD013133-sec-0040"> <h5 class="title">Subgroup analyses</h5> <p> <ol id="CD013133-list-0009"> <li> <p>Gestational age at birth (&lt; 28 weeks' gestation, 28 to 32 completed weeks' gestation, 33 to 36 completed weeks' gestation) </p> </li> <li> <p>Birth weight (&lt; 1000 grams, 1000 to 1500 grams, 1501 to 2500 grams)</p> </li> <li> <p>Chronological age (&lt; 3 days, 3 to 7 days; &gt; 7 days)</p> </li> <li> <p>Route of administration (intravenous indomethacin, oral indomethacin)</p> </li> <li> <p>Higher‐dose versus lower‐dose indomethacin: low dose (≤ 0.4 mg/kg/dose) versus high dose (&gt; 0.4 mg/kg/dose) </p> </li> <li> <p>Cumulative indomethacin dose: standard or lower cumulative dose (≤ 0.6 mg/kg) versus higher cumulative dose (&gt; 0.6 mg/kg) </p> </li> <li> <p>Method of PDA diagnosis (clinical diagnosis, echocardiographic diagnosis, Doppler diagnosis) </p> </li> <li> <p>Trial methods (low bias, high bias)</p> </li> <li> <p>Co‐interventions (antenatal steroids, postnatal surfactant therapy)</p> </li> </ol> </p> </section> </section> <section id="CD013133-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to determine whether or not findings were affected by inclusion of only studies that reported adequate methods (low risk of bias), defined as adequate randomization and allocation concealment, blinding of intervention and measurement, and up to and including 10% loss to follow‐up. </p> </section> <section id="CD013133-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE Handbook</a> (<a href="./references#CD013133-bbs2-0070" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>), to assess the certainty of the evidence for the following (clinically relevant) outcomes. </p> <section id="CD013133-sec-0043"> <h5 class="title">Efficacy</h5> <p> <ol id="CD013133-list-0010"> <li> <p>Failure of PDA closure within one week of administration of the first dose of indomethacin</p> </li> <li> <p>Proportion of infants requiring surgical ligation or transcatheter occlusion</p> </li> <li> <p>Bronchopulmonary dysplasia defined as supplemental oxygen need at 28 days postnatal age (<a href="./references#CD013133-bbs2-0024" title="BancalariE , AbdenourGE , FellerR , GannonJ . Bronchopulmonary dysplasia: clinical presentation. Journal of Pediatrics1979;95(5 Pt 2):819-23. [DOI: 10.1016/s0022-3476(79)80442-4] [PMID: 385815]">Bancalari 1979</a>) </p> </li> <li> <p>Bronchopulmonary dysplasia defined as supplemental oxygen need at 36 weeks' postmenstrual age with or without compatible clinical and radiographic findings (<a href="./references#CD013133-bbs2-0072" title="ShennanAT , DunnMS , OhlssonA , LennoxK , HoskinsEM . Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics1988;82(4):527-32. [PMID: 3174313]">Shennan 1988</a>)) </p> </li> <li> <p>All‐cause neonatal mortality at 28 days and prior to hospital discharge</p> </li> <li> <p>NEC (≥ Bell stage 2) (<a href="./references#CD013133-bbs2-0026" title="BellMJ , TernbergJL , FeiginRD , KeatingJP , MarshallR , BartonL , et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery1978;187(1):1-7. [DOI: 10.1097/00000658-197801000-00001] [PMID: 413500]">Bell 1978</a>) </p> </li> </ol> </p> </section> <section id="CD013133-sec-0044"> <h5 class="title">Safety outcomes (harms)</h5> <p> <ol id="CD013133-list-0011"> <li> <p>Mucocutaneous or gastrointestinal bleeding</p> </li> </ol> </p> <p>Two review authors (SM, RS) independently assessed the certainty of the evidence for each of the outcomes above. We considered evidence from RCTs as high certainty but downgraded the certainty of the evidence by one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates, and presence of publication bias. We used the GRADEpro Guideline Development Tool to create <a href="./full#CD013133-tbl-0001">summary of findings Table 1</a> to report the certainty of the evidence (<a href="./references#CD013133-bbs2-0046" title="GRADEpro GDT. Version accessed 9 November 2018. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence as one of four grades. </p> <p> <ol id="CD013133-list-0012"> <li> <p>High certainty: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low certainty: we are very uncertain about the estimate.</p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013133-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013133-sec-0045"></div> <section id="CD013133-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD013133-sec-0047"> <h4 class="title">Results of the search</h4> <p>The literature search on 31 July 2020 yielded 1085 studies. An ongoing clinical trial was identified in the search of clinical trial registries (<a href="./references#CD013133-bbs2-0022" title="NCT03456336. Management of the PDA Trial (PDA) [Management of the patent ductus arteriosus in premature infants trial (PDA Trial)]. clinicaltrials.gov/ct2/show/NCT03456336 (first received 7 March 2018). ">NCT03456336</a>), along with one study awaiting classification (<a href="./references#CD013133-bbs2-0021" title="ClymanRI , LiebowitzM , KaempfJ , ErdeveO , BulbulA , HåkanssonS , et al, PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. Journal of Pediatrics2019;205:41-8.e6. [DOI: 10.1016/j.jpeds.2018.09.012] [PMID: 30340932]">Clyman 2019</a>) (<a href="#CD013133-fig-0001">Figure 1</a>). See <a href="./references#CD013133-sec-0141" title="">Characteristics of ongoing studies</a> and <a href="./references#CD013133-sec-0140" title="">Characteristics of studies awaiting classification</a> . </p> <div class="figure" id="CD013133-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013133-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013133-sec-0048"> <h4 class="title">Included studies</h4> <p>We included in this review 14 clinical trials that enrolled 880 infants. Individual study characteristics, inclusion criteria, treatment details, outcome details, and study author information can be found in the <a href="./references#CD013133-sec-0138" title="">Characteristics of included studies</a> table. </p> <p><a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a> conducted a single‐center RCT to compare the efficacy of intravenous indomethacin versus standard medical management. Ventilator‐dependent preterm infants with symptomatic PDA were randomized to receive intravenous indomethacin without digoxin (n = 9) or a standard protocol that included anti‐congestive measures and digoxin (n = 9). Indomethacin treatment was allowed 6 to 19 days after study enrollment if infants remained ventilator‐dependent. Demographic characteristics did not differ between groups. Infants who had received indomethacin experienced high rates of ductal closure within 24 hours of administration (100% versus 37.5%) and achieved extubation within 72 hours (100% versus 37.5%). </p> <p><a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a> conducted a multi‐center RCT to compare the efficacy of indomethacin with standard medical management versus medical management alone for treatment of symptomatic PDA. The study was conducted at 13 tertiary care centers as part of the National Collaborative Study on Patent Ductus Arteriosus. Infants weighing less than 1750 grams with evidence of a hemodynamically significant PDA were enrolled (n = 421). Infants were randomly assigned to receive three doses of intravenous indomethacin while the control group received standard medical therapy, which included fluid restriction, diuretic use, and occasional digoxin. Infants receiving standard medical therapy were given indomethacin or underwent surgical ligation if they failed to improve within 36 to 48 hours after initiation of therapy. Permanent PDA closure occurred at a higher rate among infants who received indomethacin (79% versus 28.1%). As most patients assigned to standard medical therapy received indomethacin after failure of ductal closure, other outcomes were not considered in this analysis. </p> <p>Peckham 1984 conducted one‐year follow‐up of patients enrolled in <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>. Two hundred seventy‐one infants were examined at one year, allowing comparisons between three treatment strategies: (1) immediate administration of IV indomethacin in addition to standard medical therapy with surgery as a backup measure, (2) standard medical therapy alone initially, with indomethacin as the backup followed by surgery, and (3) standard medical management with surgery alone as backup. Cumulative mortality from trial entry to one year was 21% and did not vary between treatment strategies. No significant differences in Bayley scores or rates of BPD were noted between groups. The rate of ROP was lower in those who received indomethacin (2% and 4%) compared to those who could receive surgery alone (10%). </p> <p><a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a> completed a multi‐center, double‐blind RCT to compare the efficacy of indomethacin versus placebo for infants diagnosed with a large PDA. This study was conducted at three Australian neonatal intensive care units (NICUs). Infants born at less than 29 weeks who had a screening cardiac ultrasound demonstrating a large PDA were included (n = 92). Infants were randomly given three doses of indomethacin (n = 44) or three doses of placebo (n = 48). No differences in death, BPD, NEC, or sepsis were noted between groups. A trend towards less IVH in the indomethacin group was evident (4.5% versus 12.5%), although this did not reach statistical significance. The study abstract was published in 2012 as a conference proceeding that showed identical results as mentioned above (Kluckow 2012). Varghese and colleagues reported two‐ to three‐year neurodevelopmental outcomes of randomized infants as a conference proceeding. Follow‐up data were available for 137/149 (92%) surviving infants at mean corrected age of 25 months. Neurodevelopmental outcomes were assessed using the Bayley III Scale for all but five infants who had Griffiths scores (Griffiths Mental Development Scales ‐ Extended Revised (GMDS‐ER)). Moderate/severe cognitive delay was seen in 2.6% of infants randomized to the indomethacin group versus 9.7% in the placebo group. Moderate/severe motor delay was noted in 2.6% of infants in the indomethacin group versus 4.8% in the placebo group, and moderate/severe language delay was found in 5.2% versus 9.7% of infants, respectively (Varghese 2016). </p> <p><a href="./references#CD013133-bbs2-0004" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47:88. ">Knight 2011</a> conducted a feasibility study comparing the efficacy of IV indomethacin versus placebo for infants with a hemodynamically significant PDA. Infants were enrolled if they were at less than 28 weeks' gestational age or weighed less than 1250 grams with a PDA ≥ 1.5 mm and reversed descending aortic diastolic flow. The IV indomethacin group (n = 13) received indomethacin 200/100 mcg/kg IV every 24 hours for six days, and the control group (n = 13) received placebo. No major differences in patient demographics were noted, nor were any differences in peak inspiratory pressure and inspired oxygen for either group during therapy. This study contributed no data to the meta‐analysis. </p> <p><a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a> conducted a randomized trial to compare the efficacy of intravenous indomethacin for PDA treatment versus no intervention. Newborn infants (n = 27) weighing less than 1500 grams, ventilator‐dependent at 24 hours of age, with a physiologically significant PDA were enrolled. Infants were randomly assigned to receive three doses of intravenous indomethacin between 72 and 96 hours of life or no treatment. Infants who received indomethacin had a tendency for higher PDA closure rates within one week of administration of indomethacin (58% versus 13%). No differences were reported in all‐cause mortality at discharge, the proportion of infants requiring surgical ligation of PDA, or the duration of oxygen dependence. </p> <p><a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a> conducted an RCT in the NICU of the University of Rochester to compare the efficacy of intravenous indomethacin and standard medical management to achieve closure of a hemodynamically significant PDA. Newborn infants weighing 1350 grams or less who had severe respiratory distress and ventilatory failure requiring intermittent mandatory ventilation (IMV) during the first hours of life were considered eligible for inclusion. Those with clinical and radiographic signs of PDA were enrolled, and infants were randomized to receive 0.2 mg/kg indomethacin (n = 12) every 24 hours for up to three days or medical management (n = 13), including fluid restriction and/or furosemide 1 to 2 mg/kg every 12 hours. The medical management group was not excluded from receiving indomethacin nor from undergoing surgical ligation after therapies failed to eliminate pulmonary hyperperfusion through the PDA. Although rates of mortality were higher in the control group (30.8% versus 9.1%), they did not reach the level of statistical significance. A difference in BPD was reported between control and indomethacin groups (66.7 versus 18.2%). In the control group, 11/13 infants developed symptoms of congestive heart failure (CHF) and required indomethacin rescue at a mean age of 167.4 hours of life. No significant difference in duration of assisted ventilation was evident between control and intervention groups (7.3 ± 2.5 days versus 7.6 ± 6.05 days). </p> <p><a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a> conducted a randomized trial comparing intravenous indomethacin versus no intervention for treatment of symptomatic PDA in preterm infants. In this study, 24 preterm infants with symptomatic PDA were randomized to receive either 0.2 mg IV indomethacin just after diagnosis (n = 12) or no treatment for 48 hours (n = 12). Among 12 infants in the intervention group, the PDA closed within 4 to 26 hours of the first dose in eight cases. In all 12 untreated infants, the PDA persisted for at least 48 hours. Ten of the 12 untreated infants subsequently received IV (n = 5) or oral (n = 5) indomethacin. </p> <p><a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a> conducted a single‐center RCT to compare the efficacy of indomethacin versus placebo for treatment of hemodynamically significant PDA. The study was conducted in the NICU at University of Arkansas for Medical Sciences or at St. Vincent’s Infirmary, Little Rock, Arizona, USA. Newborn infants (n = 23) at less than 35 weeks' gestational age (GA) with large left‐to‐right PDA determined by clinical signs, radiography, and echo or cardiac catheterization were enrolled. Infants were randomized to receive oral indomethacin (n = 12) or placebo (n = 11). The indomethacin group received 0.2 mg/kg every 12 hours up to three doses, and the placebo group received the same volume of saline at the same interval. PDA closure occurred at a higher rate among infants receiving indomethacin compared to those receiving placebo (58% versus 18%). </p> <p><a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a> conducted a single‐center, randomized cross‐over study to compare the efficacy of oral indomethacin versus placebo for closure of clinically significant PDA. Infants (n = 21) with RDS and a clinically significantly PDA who had failed to respond to fluid restriction were enrolled. Infants were randomly assigned to up to two oral doses of 0.25 mg/kg indomethacin or placebo. If infants demonstrated signs of a clinically significant PDA at 48 hours, they received the alternative treatment one time. Infants receiving indomethacin had a PDA closure rate higher than those receiving placebo before cross‐over (80% versus 27.2%). </p> <p><a href="./references#CD013133-bbs2-0010" title="OsbornDA , EvansN , KluckowM . Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2003;88(6):F477-82. [DOI: 10.1136/fn.88.6.f477] [PMID: 14602694]">Osborn 2003</a> conducted a multi‐center RCT to compare the efficacy of intravenous indomethacin and placebo in maintaining superior vena cava (SVC) flow rates in preterm infants with significant PDA. Newborn infants (n = 70) born at gestational age &lt; 30 weeks, &lt; 12 hours of life, with a PDA Doppler diameter &gt; 1.6 mm were eligible. Infants randomly received a single dose of 0.2 mg/kg intravenous indomethacin (n = 35) or saline (n = 35). Infants were evaluated by echocardiography one hour following infusion, and were crossed over to the other treatment if PDA remained &gt; 1.6 mm and if &lt; 30% constriction from initial diameter occurred. No significant differences in mean per cent change in DA diameter (‐20% versus –15%), SVC flows (‐3.2 to 10.5 mL/kg/min), or change in mean blood pressure (+1.4 mmHg versus +0.1 mmHg) were noted one hour after infusion. </p> <p><a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a> conducted a single‐center RCT to evaluate the efficacy of oral indomethacin compared to placebo to achieve closure of hemodynamically significant PDA. Newborn infants (n = 15) weighing &lt; 1500 grams with a clinically significant PDA were fluid‐restricted for 24 hours and were randomized to receive up to three doses (0.2 mg/kg) of oral indomethacin (n = 15) or placebo (n = 15). PDA closure occurred in 13/15 (87%) of those receiving indomethacin compared to 3/15 (20%) of those receiving placebo. Six infants receiving indomethacin had relapses at a mean of eight days, tended to weigh less and have a lower GA, and were younger at time of treatment. Infants who failed placebo or relapsed could be given indomethacin on an open basis. 6/11 (54.5%) of infants in the control group achieved ductal closure following open indomethacin administration. Of the 15 infants who did not respond to indomethacin, nine achieved spontaneous ductal closure, and three required surgical closure. Three infants died before PDA closure. </p> <p><a href="./references#CD013133-bbs2-0012" title="ValaesT , MoylanFM , CohnH , ChungK , NagpaulK , ChrenoffHL , et al. Incidence and significance of PDA in preterm infants (PTI) and controlled blind trial of indomethacin (IND). Pediatric Research1980;14:452. ">Valaes 1980</a> conducted a single‐center RCT to compare the efficacy of oral indomethacin and placebo for closure of a symptomatic PDA. Preterm infants (n = 13) with evidence of a symptomatic PDA were randomized to receive up to three doses (0.2 mg/kg) oral indomethacin (n = 7) or placebo (n = 6). Among patients receiving indomethacin, 3/7 achieved PDA closure and the remainder became asymptomatic; 2/6 patients receiving placebo had ductal closure and the other 4 remained symptomatic. The four patients were given indomethacin at an unspecified time; three patients achieved ductal closure, and one became asymptomatic. </p> <p><a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a> conducted an RCT to compare the efficacy of oral indomethacin versus placebo for treatment of symptomatic PDA. Thirty‐nine preterm infants with RDS requiring ventilator support with symptomatic PDA (defined as left atrial‐to‐aortic root ratio ≥ 1.3) who had failed a 24‐hour course of standardized medical management were randomized to indomethacin (0.2 mg/kg of enteral indomethacin) or placebo in a double‐blind manner. Second and third indomethacin doses were administered at 24‐hour intervals in phase 1 (n = 17), and at eight‐hour intervals in phase 2 (n = 22). The PDA closure rate in phase 1 was 75% in the indomethacin group versus 44% in the placebo group. In phase 2, the PDA closure rate in the indomethacin group was 85% versus only 11% in the placebo group (P &lt; 0.01). In this review, we have synthesized study results by combining results from the two phases. </p> <p><a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a> conducted an RCT to compare the effects of intravenous indomethacin versus placebo for closure of significant PDA. Infants (n = 55) weighing &lt; 2040 grams or transferred to the study site with evidence of cardiovascular dysfunction due to a PDA were included after failure of medical management. Ductal closure was achieved at a higher rate among those receiving indomethacin than in those receiving placebo (92.9% versus 37.0%), and surgical ligation rates were lower (3.6% versus 29.5%). Rates of mortality before discharge, NEC, and late‐onset sepsis were similar between groups. </p> <p><a href="./references#CD013133-bbs2-0079" title="YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one-year follow-up. American Journal of Diseases of Children1982;136(9):803-7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]">Yeh 1982b</a> conducted one‐year follow‐up of infants enrolled in <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>. Three further infants in both indomethacin and control groups died at one year (32.1% versus 29.6%). Of the 38 surviving infants, 30 (indomethacin = 13, control = 17) presented for one‐year follow‐up. It was noted that there had been further surgical ligation, including one case in the indomethacin group and four in the control group. Two infants in the control group had Mental Developmental Index (MDI) and Psychomotor Developmental Index (PDI) scores &lt; 50. None in the indomethacin group had Bayley scores &lt; 70. Study authors categorized survivors as having a composite major and minor neurological deficit; 5/13 (38%) of those receiving indomethacin and 7/17 (41%) of those receiving control had this composite outcome. Additionally, three (23%) infants receiving indomethacin had abnormal electroencephalogram (EEG) findings compared to seven (41%) in the control group. The mean MDI and PDI scores for the indomethacin group were 100.8 ± 24.6 and 92.4 ± 16.9. The group receiving placebo had an MDI of 97.7 ± 29.6 and a PDI of 103.4 ± 29.2. </p> <p><a href="./references#CD013133-bbs2-0081" title="YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]">Yeh 1983</a> reported on the incidence of ROP in 47 infants from the <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a> trial. 2/24 (8%) infants receiving indomethacin and 6/23 (26%) receiving placebo developed ROP. Severe ROP developed in 1/24 (4%) receiving indomethacin and in 1/23 (4%) of those receiving saline. </p> <p><a href="./references#CD013133-bbs2-0080" title="YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]">Yeh 1982c</a> reported on plasma glucose levels following indomethacin administration in 47 infants of the <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a> cohort. No statistical differences in baseline plasma glucose or daily caloric or IV glucose intake before and during the study were noted. Infants receiving indomethacin (n = 25) had plasma glucose of 70.8 ± 3.9 at 24 hours and 70.9 ± 5.9 at 49 hours, and those receiving placebo (n = 22) had plasma glucose of 94.2 ± 3.4 at 24 hours and 90.4 ± 4.1 at 48 hours. </p> <p><a href="./references#CD013133-bbs2-0078" title="YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981b</a> reported on left atrium (LA): aorta at the level of the aortic valve (Ao), left ventricular end‐diastolic diameter (LVEDD) on echocardiogram, change in tidal volume, and lung compliance in 11 infants of the <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a> cohort who did not require mechanical ventilation. Significant pretreatment and post‐treatment changes in tidal volume, lung compliance, LA:Ao, and LVEDD were evident among those who received indomethacin but not in those receiving placebo. No changes in fraction of inspired oxygen (FiO₂) requirements, pH, or base deficit pretreatment and post‐treatment were reported for either group. </p> </section> <section id="CD013133-sec-0049"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies (see <a href="./references#CD013133-sec-0139" title="">Characteristics of excluded studies</a>). </p> <p><a href="./references#CD013133-bbs2-0015" title="CarmoK , EvansN , ParadisisM . Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography. Journal of Pediatrics2009;155(6):819-22. [DOI: 10.1016/j.jpeds.2009.06.013] [PMID: 19643435]">Carmo 2009</a> conducted a single‐center, non‐blinded RCT at a perinatal center in Australia. Infants at &lt; 30 weeks' GA, requiring respiratory support and found to have a PDA &gt; 2 mm on echocardiogram performed between 3 and 12 hours of age, were included. All infants were initially given an indomethacin dose of 0.1 mg/kg. Infants were than randomized to receive 0.1 mg/kg indomethacin every 24 hours only if their ductal diameter remained &gt; 1.6 mm, or to receive 0.1 mg/kg every 24 hours up to three total doses. The primary outcome was failure of PDA closure, defined as ductal patency 24 hours after the final dose of indomethacin. No differences between groups in failure of PDA closure, PDA reopening, or need for rescue therapy (medical or ligation) were noted. Fewer doses of indomethacin were given in the targeted therapy group. This study was excluded because infants in both groups received indomethacin. </p> <p><a href="./references#CD013133-bbs2-0016" title="MardoumR , BejarR , MerrittT , BerryC . Controlled study of the effects of indomethacin on cerebral blood flow velocities in newborn infants. Journal of Paediatrics1991;118(1):112-5. [DOI: 10.1016/s0022-3476(05)81860-8] [PMID: 1986076]">Mardoum 1991</a> conducted a single‐center RCT at a perinatal center in the USA. Preterm infants with clinically significant PDA were enrolled if they had adequate arterial catheterization and continuous intra‐arterial monitoring of blood pressure, as well as transcutaneous monitoring of oxygen and carbon dioxide pressure. Infants were randomized to receive intravenous indomethacin 0.2 mg/kg or placebo. Infants were crossed‐over to receive the alternative therapy after 30 minutes. The primary outcome was cerebral blood flow velocity. We excluded this study as infants were given indomethacin regardless of their PDA status after initial treatment. </p> <p><a href="./references#CD013133-bbs2-0017" title="MullettM , CroghanT , MyerbergD , KrallJ , NealW . Indomethacin for closure of patent ductus arteriosus in prematures. Clinical Pediatrics1982;21(4):217-20. [DOI: 10.1177/000992288202100404] [PMID: 7039927]">Mullett 1982</a> conducted a randomized, double‐blind trial of preterm infants with birth weight &lt; 1750 grams and a systolic murmur consistent with a PDA. Infants received either 0.2 mg/kg/dose of oral indomethacin two doses 24 hours apart or placebo. The primary outcome was PDA closure. We excluded this study as infants with PDA, regardless of symptomatic status, were included. </p> <p><a href="./references#CD013133-bbs2-0018" title="NairP , KaranS . Indomethacin for closure of patent ductus arteriosous in preterm neonates. Indian Journal of Pediatrics1986;53(4):499-503. [DOI: 10.1007/BF02749534] [PMID: 28391570]">Nair 1986</a> conducted a randomized trial at a perinatal center in India. All infants with a PDA diagnosis were included. Infants were randomized to receive either 0.2 mg/kg three times at 12‐hour intervals or to no treatment. The primary outcome was PDA closure. The rate of ductal closure was higher among those receiving indomethacin (60%) compared to those given no treatment (16.7%). We excluded this study as it did not specify whether infants had a clinically significant PDA. </p> <p><a href="./references#CD013133-bbs2-0019" title="NuntnarumitP , ChongkongkiatP , KhositsethA . N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm infants. Acta Pædiatrica2011;100(9):1217-21. [DOI: 10.1111/j.1651-2227.2011.02304.x] [PMID: 21457304]">Nuntnarumit 2011</a> conducted a trial evaluating use of NT‐proBNP levels to guide indomethacin therapy at a single perinatal center in Thailand. Infants at &lt; 33 weeks' GA were enrolled. Infants with N‐terminal pro hormone B‐type natriuretic peptide (NT‐proBNP) &gt; 10,180 pg ⁄ mL on day of life 2 were given three doses of 0.1 mg/kg IV indomethacin at 24‐hour intervals. Of the remaining infants, those who developed clinical symptoms of hemodynamically significant PDA, defined as the presence of left‐to‐right ductal shunting plus at least two clinical signs (heart murmur, heart rate (HR) &gt; 160 beats per minutes (BPM), pulse pressure &gt; 25 mmHg, hyperactive precordium, bounding pulse, hepatomegaly, increasing respiratory support by 20% increase in oxygen supplementation or in pressure support, chest radiographic evidence of cardiomegaly or pulmonary congestion) received three doses of 0.1 mg/kg IV indomethacin at 12‐hour intervals. This course could be repeated if clinical signs persisted. If infants in the NT‐proBNP guided group developed clinical signs attributable to a hemodynamically significant PDA, the treatment interval was moved to every 12 hours. Primary outcomes were incidence of hemodynamically significant PDA and rate of exposure to indomethacin. 19 (38%) infants had NT‐proBNP greater than threshold and were treated with indomethacin. Only 2/19 (10.5%) had no echocardiographic evidence of PDA at the time of NT‐proBNP collection. None of the early treatment group developed significant PDA; 1/31 infants with NT‐proBNP below cutoff developed a significant PDA requiring treatment. This study was not included in this review as it was not randomized. </p> <p><a href="./references#CD013133-bbs2-0020" title="YehTF , WilksA , SinghJ , BetkerurM , LilienL , PildesRS . Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus. Journal of Pediatrics1982;101(3):433-7. [DOI: 10.1016/s0022-3476(82)80079-6] [PMID: 7108667]">Yeh 1982a</a> conducted a randomized study at a single center in the USA. Infants with PDA, clinical evidence of cardiovascular dysfunction, and LA:Ao ≥ 1.3 were randomized to receive 0.3 mg/kg IV indomethacin and 1 mg/kg IV furosemide or 0.3 mg/kg IV indomethacin. Primary outcomes included urine output, fractional excretion of sodium and chloride, and glomerular filtration rate (GFR). The same number of infants in each group had PDA closure. Those in the furosemide had higher urine output, fractional excretion of sodium and chloride, and GFR. We excluded this study from this review as both groups received indomethacin. </p> </section> </section> <section id="CD013133-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>Many studies were conducted over 30 years ago. In subsequent years, methodological expectations have changed, with greater care taken to minimize bias and to report details of trial conduct (<a href="#CD013133-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD013133-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013133-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013133-sec-0051"> <h4 class="title">Allocation</h4> <section id="CD013133-sec-0052"> <h5 class="title">1. Random sequence generation</h5> <p>Most studies randomized infants using a random numbers generator (<a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>), or the method of randomization was unclear (<a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>; <a href="./references#CD013133-bbs2-0010" title="OsbornDA , EvansN , KluckowM . Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2003;88(6):F477-82. [DOI: 10.1136/fn.88.6.f477] [PMID: 14602694]">Osborn 2003</a>; <a href="./references#CD013133-bbs2-0012" title="ValaesT , MoylanFM , CohnH , ChungK , NagpaulK , ChrenoffHL , et al. Incidence and significance of PDA in preterm infants (PTI) and controlled blind trial of indomethacin (IND). Pediatric Research1980;14:452. ">Valaes 1980</a>). </p> <p><a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a> randomized by block numbers to receive either oral indomethacin or placebo. <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a> randomized by number code by batching of 10, and <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a> used block randomization by gestational age and by center using a random number‐generating table. </p> </section> <section id="CD013133-sec-0053"> <h5 class="title">2. Allocation concealment</h5> <p>In most studies, the method of allocation concealment was unclear (<a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>: <a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>: <a href="./references#CD013133-bbs2-0010" title="OsbornDA , EvansN , KluckowM . Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2003;88(6):F477-82. [DOI: 10.1136/fn.88.6.f477] [PMID: 14602694]">Osborn 2003</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013133-bbs2-0012" title="ValaesT , MoylanFM , CohnH , ChungK , NagpaulK , ChrenoffHL , et al. Incidence and significance of PDA in preterm infants (PTI) and controlled blind trial of indomethacin (IND). Pediatric Research1980;14:452. ">Valaes 1980</a>). <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a> and <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a> placed allocation inside concealed envelopes. <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a> concealed allocation from both physician and pharmacist, and randomization numbers were kept by a pharmacist not involved in patient care in <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>. </p> </section> </section> <section id="CD013133-sec-0054"> <h4 class="title">Blinding</h4> <p>In five studies, staff were not blinded to the drug administered (<a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>), or blinding was not reported as it is unlikely to have occurred (<a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0012" title="ValaesT , MoylanFM , CohnH , ChungK , NagpaulK , ChrenoffHL , et al. Incidence and significance of PDA in preterm infants (PTI) and controlled blind trial of indomethacin (IND). Pediatric Research1980;14:452. ">Valaes 1980</a>). </p> <section id="CD013133-sec-0055"> <h5 class="title">Blinding</h5> <p>Other studies were more successful in blinding the intervention using a placebo (<a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>: <a href="./references#CD013133-bbs2-0010" title="OsbornDA , EvansN , KluckowM . Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2003;88(6):F477-82. [DOI: 10.1136/fn.88.6.f477] [PMID: 14602694]">Osborn 2003</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). One study stated that staff were blinded to drug administration without communicating details of how this occurred (<a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). </p> </section> </section> <section id="CD013133-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>All randomized infants are accounted for in all 12 of the 14 included studies that contributed to the meta‐analysis (<a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013133-bbs2-0012" title="ValaesT , MoylanFM , CohnH , ChungK , NagpaulK , ChrenoffHL , et al. Incidence and significance of PDA in preterm infants (PTI) and controlled blind trial of indomethacin (IND). Pediatric Research1980;14:452. ">Valaes 1980</a>; <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>). </p> </section> <section id="CD013133-sec-0057"> <h4 class="title">Selective reporting</h4> <p>Most trials were conducted before the routine expectation of trials registration (<a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>; <a href="./references#CD013133-bbs2-0010" title="OsbornDA , EvansN , KluckowM . Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2003;88(6):F477-82. [DOI: 10.1136/fn.88.6.f477] [PMID: 14602694]">Osborn 2003</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013133-bbs2-0012" title="ValaesT , MoylanFM , CohnH , ChungK , NagpaulK , ChrenoffHL , et al. Incidence and significance of PDA in preterm infants (PTI) and controlled blind trial of indomethacin (IND). Pediatric Research1980;14:452. ">Valaes 1980</a>; <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). Therefore, selective bias was difficult to interpret. </p> <p>Only one study was formally registered, and no deviations from the original protocol were reported (<a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). </p> </section> <section id="CD013133-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>None were noted.</p> </section> </section> <section id="CD013133-sec-0059"> <h3 class="title" id="CD013133-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD013133-tbl-0001"><b>Summary of findings 1</b> Indomethacin compared to placebo or control for symptomatic patent ductus arteriosus in preterm infants</a> </p> <section id="CD013133-sec-0060"> <h4 class="title">Indomethacin versus placebo or control (Comparison 1)</h4> <p>Out of the 14 included trials, 12 trials contributed to the meta‐analysis. Pooled results from these 12 trials are discussed in detail below (<a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013133-bbs2-0012" title="ValaesT , MoylanFM , CohnH , ChungK , NagpaulK , ChrenoffHL , et al. Incidence and significance of PDA in preterm infants (PTI) and controlled blind trial of indomethacin (IND). Pediatric Research1980;14:452. ">Valaes 1980</a>; <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). </p> <section id="CD013133-sec-0061"> <h5 class="title">Primary outcomes</h5> <section id="CD013133-sec-0062"> <h6 class="title">Failure of PDA closure within one week of administration of the first dose of indomethacin (Outcome 1.1) </h6> <p>Ten studies reported on PDA closure within one week of administration of the first dose of indomethacin (parenteral administration: <a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>; enteral administration: <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013133-bbs2-0012" title="ValaesT , MoylanFM , CohnH , ChungK , NagpaulK , ChrenoffHL , et al. Incidence and significance of PDA in preterm infants (PTI) and controlled blind trial of indomethacin (IND). Pediatric Research1980;14:452. ">Valaes 1980</a>; <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>). Many individual studies reported increased rates of PDA closure within one week of indomethacin administration (parenteral administration: <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>, enteral administration: <a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>). Overall, indomethacin administration was associated with a large decrease in failure of PDA closure within one week of administration of the first dose of indomethacin (typical risk ratio (RR) 0.30, 95% confidence interval (CI) 0.23 to 0.38; typical risk difference (RD) ‐0.52, 95% CI ‐0.58 to ‐0.45; 10 studies, 654 infants; high‐certainty evidence; <a href="./references#CD013133-fig-0004" title="">Analysis 1.1</a>; <a href="#CD013133-fig-0003">Figure 3</a>). This was seen in both studies that utilized enteral (typical RR 0.35, 95% CI 0.23 to 0.54; typical RD ‐0.49, 95% CI ‐0.64 to ‐0.35; 5 studies, 126 infants) or parenteral administration of indomethacin (typical RR 0.28, 95% CI 0.21 to 0.37; typical RD ‐0.52, 95% CI ‐0.60 to ‐0.45; 5 studies, 528 infants). </p> <div class="figure" id="CD013133-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Indomethacin vs placebo or control, outcome: 1.1 Failure of PDA closure within 1 week of administration of the first dose of indomethacin." data-id="CD013133-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Indomethacin vs placebo or control, outcome: 1.1 Failure of PDA closure within 1 week of administration of the first dose of indomethacin. </p> </div> </div> </div> </section> <section id="CD013133-sec-0063"> <h6 class="title">Bronchopulmonary dysplasia (defined as supplemental oxygen need at 28 days' postnatal age with or without compatible clinical and radiographic findings) (Outcome 1.2) </h6> <p>Only one study reported on supplemental oxygen need at 28 days' postnatal age with or without compatible clinical and radiographic findings (parenteral administration: <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). In that small study, no impact on the risk of requiring supplemental oxygen at 28 days' postnatal age was reported (RR 1.45, 95% CI 0.60 to 3.51; 1 study, 55 infants; low‐certainty evidence; <a href="./references#CD013133-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD013133-sec-0064"> <h6 class="title">Bronchopulmonary dysplasia (defined as supplemental oxygen at 36 weeks' postmenstrual age with or without compatible clinical and radiographic findings) (Outcome 1.3) </h6> <p>Only one study reported on supplemental oxygen need at 36 weeks' postmenstrual age with or without compatible clinical and radiographic findings (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). In that study, no impact on the risk of requiring supplemental oxygen at 36 weeks' postmenstrual age was reported (RR 0.80, 95% CI 0.41 to 1.55; 1 study, 92 infants; low‐certainty evidence; <a href="./references#CD013133-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD013133-sec-0065"> <h6 class="title">All‐cause neonatal mortality at 28 days</h6> <p>This was not reported.</p> </section> <section id="CD013133-sec-0066"> <h6 class="title">All‐cause neonatal mortality before hospital discharge (Outcome 1.4)</h6> <p>Eight studies reported on all‐cause neonatal mortality before hospital discharge (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>; enteral administration: <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>). None of the individual studies reported an impact on all‐cause neonatal mortality before hospital discharge, and no effect of either parenteral or enteral indomethacin was demonstrated in the meta‐analysis (all studies typical RR 0.78, 95% CI 0.46 to 1.33; 8 studies, 314 infants; parenteral administration typical RR 1.00, 95% CI 0.52 to 1.91; 5 studies, 222 infants; enteral administration typical RR 0.46, 95% CI 0.17 to 1.22; 3 studies, 92 infants; moderate‐certainty evidence; <a href="./references#CD013133-fig-0007" title="">Analysis 1.4</a>). No heterogeneity was noted. </p> </section> </section> <section id="CD013133-sec-0067"> <h5 class="title">Secondary outcomes: PDA‐related outcomes</h5> <section id="CD013133-sec-0068"> <h6 class="title">Proportion of infants receiving rescue medical treatment (repeated cyclooxygenase or paracetamol/acetaminophen dosing, or both) (Outcome 1.5) </h6> <p>Six studies reported on the proportion of infants receiving rescue medical treatment (repeated cyclooxygenase or paracetamol/acetaminophen dosing, or both) (parenteral administration: <a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; enteral administration: <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>). </p> <p>Two of the six studies reported a decrease in the risk of receiving rescue medical treatment (repeated cyclooxygenase or paracetamol/acetaminophen dosing, or both) (<a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>). </p> <p>Overall, indomethacin administration was associated with a large decrease in the risk of receiving rescue medical treatment (typical RR 0.35, 95% CI 0.23 to 0.54; typical RD ‐0.34, 95% CI ‐0.45 to ‐0.22; 6 studies, 211 infants; <a href="./references#CD013133-fig-0008" title="">Analysis 1.5</a>). </p> <p>This was seen in both studies that utilized enteral (typical RR 0.23, 95% CI 0.06 to 0.82; typical RD ‐0.31, 95% CI ‐0.53 to ‐0.09; 2 studies, 53 infants) or parenteral administration of indomethacin (typical RR 0.38, 95% CI 0.24 to 0.61; typical RD ‐0.35, 95% CI ‐0.48 to ‐0.21; 4 studies, 158 infants). </p> </section> <section id="CD013133-sec-0069"> <h6 class="title">Proportion of infants requiring surgical ligation or transcatheter occlusion (Outcome 1.6) </h6> <p>Seven studies reported on the proportion of infants requiring surgical ligation or transcatheter occlusion (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>; enteral administration: <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>). </p> <p>None of the included studies reported a decrease in the risk of requiring surgical ligation or transcatheter occlusion, and no effect of either parenteral or enteral indomethacin was demonstrated in the meta‐analysis (all studies typical RR 0.66, 95% CI 0.33 to 1.29; 7 studies, 275 infants; moderate‐certainty evidence; <a href="./references#CD013133-fig-0009" title="">Analysis 1.6</a>; parenteral administration typical RR 0.50, 95% CI 0.19 to 1.33; 5 studies, 222 infants; enteral administration typical RR 0.94, 95% CI 0.37 to 2.39; 2 studies, 53 infants). No heterogeneity was noted. </p> </section> </section> <section id="CD013133-sec-0070"> <h5 class="title">Other outcomes</h5> <section id="CD013133-sec-0071"> <h6 class="title">Pneumothorax</h6> <p>This was not reported.</p> </section> <section id="CD013133-sec-0072"> <h6 class="title">Pulmonary hemorrhage (Outcome 1.7)</h6> <p>Only one study reported on pulmonary hemorrhage (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). In that study, no impact on the risk of pulmonary hemorrhage was reported (RR 0.40, 95% CI 0.14 to 1.16; 1 study, 92 infants; <a href="./references#CD013133-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD013133-sec-0073"> <h6 class="title">Late‐onset bacterial sepsis (Outcome 1.8)</h6> <p>Three studies reported on the risk of late‐onset bacterial sepsis (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>; enteral administration: <a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>). </p> <p>None of the included studies reported a decrease in the risk of late‐onset bacterial sepsis, and no effect of either parenteral or enteral indomethacin was demonstrated in the meta‐analysis (all studies typical RR 0.78, 95% CI 0.46 to 1.33; 3 studies, 170 infants; <a href="./references#CD013133-fig-0011" title="">Analysis 1.8</a>; parenteral administration typical RR 0.82, 95% CI 0.48 to 1.40; 2 studies, 147 infants; enteral administration typical RR 0.31, 95% CI 0.01 to 6.85; 1 study, 23 infants). No heterogeneity was noted. </p> </section> <section id="CD013133-sec-0074"> <h6 class="title">Necrotising enterocolitis (NEC) (≥ Bell stage 2) (Bell 1978) (Outcome 1.9)</h6> <p>Two studies, both using parenteral administration of indomethacin, reported on the risk of necrotizing enterocolitis (NEC) (≥ Bell stage 2) (<a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). </p> <p>Neither of the included studies reported a decrease in the risk of necrotizing enterocolitis, and no effect of parenteral indomethacin was demonstrated in the meta‐analysis (parenteral administration typical RR 1.27, 95% CI 0.36 to 4.55; 2 studies, 147 infants; low‐certainty evidence; <a href="./references#CD013133-fig-0012" title="">Analysis 1.9</a>). No heterogeneity was noted. </p> </section> <section id="CD013133-sec-0075"> <h6 class="title">Intraventricular hemorrhage (IVH) (any grade) (Papile 1978) (Outcome 1.10)</h6> <p>Three studies reported on the risk of intraventricular hemorrhage (IVH) (any grade) (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). </p> <p>None of the included studies reported a decrease in the risk of intraventricular hemorrhage (IVH) (any grade), and no effect of parenteral indomethacin was demonstrated in the meta‐analysis (parenteral administration typical RR 0.58, 95% CI 0.20 to 1.65; 3 studies, 171 infants; <a href="./references#CD013133-fig-0013" title="">Analysis 1.10</a>). No heterogeneity was noted. </p> </section> <section id="CD013133-sec-0076"> <h6 class="title">Severe intraventricular hemorrhage (IVH) (grade III to IV) (Papile 1978) (Outcome 1.11) </h6> <p>Only one study reported on severe IVH (grade III to IV) (parenteral administration: <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>). In that small study, no impact on the risk of severe IVH was reported (RR 0.33, 95% CI 0.01 to 7.45; 1 study, 24 infants; <a href="./references#CD013133-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD013133-sec-0077"> <h6 class="title">Periventricular leukomalacia (PVL) (Outcome 1.12)</h6> <p>Only one study reported on periventricular leukomalacia (PVL) (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). In that study, no impact on the risk of PVL was reported (RR 1.09, 95% CI 0.29 to 4.10; 1 study, 92 infants; <a href="./references#CD013133-fig-0015" title="">Analysis 1.12</a>). </p> </section> <section id="CD013133-sec-0078"> <h6 class="title">Retinopathy of prematurity (any stage) (ICROP 2005) (Outcome 1.13)</h6> <p>Only one study reported on retinopathy of prematurity (any stage) (parenteral administration: <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). In that small study, no impact on the risk of requiring supplemental oxygen at 28 days' postnatal age was reported (RR 0.32, 95% CI 0.07 to 1.42; 1 study, 47 infants; <a href="./references#CD013133-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD013133-sec-0079"> <h6 class="title">Severe retinopathy of prematurity (≥ stage III) (Outcome 1.14)</h6> <p>Only one study reported on severe retinopathy of prematurity (ROP) (≥ stage III) (parenteral administration: <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). In that small study, no impact on the risk of severe ROP was reported (RR 0.96, 95% CI 0.06 to 14.43; 1 study, 47 infants; <a href="./references#CD013133-fig-0017" title="">Analysis 1.14</a>). </p> </section> <section id="CD013133-sec-0080"> <h6 class="title">Surgery for severe retinopathy of prematurity (added post hoc) (Outcome 1.15)</h6> <p>Only one study reported on surgery for severe retinopathy of prematurity (ROP) (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). In that study, no impact on the risk of surgery for severe ROP was reported (RR 0.16, 95% CI 0.01 to 2.93; 1 study, 92 infants; <a href="./references#CD013133-fig-0018" title="">Analysis 1.15</a>). </p> </section> <section id="CD013133-sec-0081"> <h6 class="title">Infant mortality (first year of life) (Outcome 1.16)</h6> <p>Only one study reported on infant mortality (first year of life) (parenteral administration: <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). In that small study, no impact on the risk of infant mortality (first year of life) was reported (RR 1.08, 95% CI 0.49 to 2.40; 1 study, 55 infants; <a href="./references#CD013133-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD013133-sec-0082"> <h6 class="title">Use of inotropic agents (Outcome 1.17)</h6> <p>Only one study reported on use of inotropic agents (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). In that study, no impact on the risk of using inotropic agents was reported (RR 1.09, 95% CI 0.50 to 2.37; 1 study, 92 infants; <a href="./references#CD013133-fig-0020" title="">Analysis 1.17</a>). </p> </section> <section id="CD013133-sec-0083"> <h6 class="title">Duration of assisted ventilation (days) (Outcome 1.18)</h6> <p>Only one study reported on the duration of assisted ventilation (parenteral administration: <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>). In that small study, no impact on the duration of assisted ventilation was reported (mean difference (MD) 0.28, 95% CI ‐3.55 to 4.11; 1 study, 24 infants; <a href="./references#CD013133-fig-0021" title="">Analysis 1.18</a>). </p> </section> <section id="CD013133-sec-0084"> <h6 class="title">Duration of oxygen dependence (days to last discontinuation of any supplemental oxygen)</h6> <p>This was not reported.</p> </section> <section id="CD013133-sec-0085"> <h6 class="title">Duration of hospital stay (days) (Outcome 1.19)</h6> <p>Only one study reported on the duration of hospital stay (days) (parenteral administration: <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). In that small study, no impact on the duration of hospital stay (days) was reported (MD ‐14.30, 95% CI ‐51.36 to 22.76; 1 study, 44 infants; <a href="./references#CD013133-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD013133-sec-0086"> <h6 class="title">Time to full enteral feeds (days)</h6> <p>This was not reported.</p> </section> <section id="CD013133-sec-0087"> <h6 class="title">Cerebral palsy at approximately 2 years' corrected age (as defined by study authors)</h6> <p>This was not reported.</p> </section> <section id="CD013133-sec-0088"> <h6 class="title">Moderate to severe neurodevelopmental outcome: neurodevelopmental outcome at approximately 2 years' corrected age (acceptable range 18 months to 28 months) including cerebral palsy, delayed neurodevelopment (Bayley Scales of Infant Development Mental Developmental Index &lt; 70), legal blindness (&lt; 20/200 visual acuity), and hearing deficit (aided or &lt; 60 dB on audiometric testing). The composite outcome 'neurodevelopmental impairment' was defined as having any one of the aforementioned deficits </h6> <p>This was not reported.</p> </section> </section> <section id="CD013133-sec-0089"> <h5 class="title">Safety outcomes (harms reported within one week of completing intervention)</h5> <section id="CD013133-sec-0090"> <h6 class="title">Intestinal perforation (Outcome 1.20)</h6> <p>Only one study reported on Intestinal perforation (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). In that study, no cases of intestinal perforation were reported in either group (RR not estimable; RD 0.00, 95% CI ‐0.04 to 0.04; 1 study, 92 infants; <a href="./references#CD013133-fig-0023" title="">Analysis 1.20</a>). </p> </section> <section id="CD013133-sec-0091"> <h6 class="title">Renal function</h6> <section id="CD013133-sec-0092"> <p><b>Oliguria (&lt; 1 mL/kg/hr)</b></p> <p>This was not reported.</p> </section> <section id="CD013133-sec-0093"> <p><b>Serum/plasma creatinine (µmol/L) levels during treatment</b></p> <p>This was not reported.</p> </section> <section id="CD013133-sec-0094"> <p><b>Serum/plasma creatinine (µmol/L) after treatment</b></p> <p>This was not reported.</p> </section> </section> <section id="CD013133-sec-0095"> <h6 class="title">Post hoc: <i>c</i>reatinine &gt; 150 µmol/L during treatment (post hoc) (Outcome 1.21) </h6> <p>Only one study reported on creatinine &gt; 150 µmol/L during treatment (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). In that study, no impact on the risk of elevation in creatinine &gt; 150 µmol/L during treatment was reported (RR 1.09, 95% CI 0.07 to 16.92; 1 study, 92 infants; <a href="./references#CD013133-fig-0024" title="">Analysis 1.21</a>). </p> </section> <section id="CD013133-sec-0096"> <h6 class="title">Hemostasis</h6> <section id="CD013133-sec-0097"> <p><b>Mucocutaneous or gastrointestinal bleeding (Outcome 1.22)</b></p> <p>Two studies reported on the risk of mucocutaneous or gastrointestinal bleeding (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; enteral administration: <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>). </p> <p>None of the included studies reported a decrease in the risk of mucocutaneous or gastrointestinal bleeding. <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a> reported no events (RR not estimable; RD 0.00, 95% CI ‐0.04 to 0.04; 1 study, 89 infants), and <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a> reported one event in the control group (RR 0.33, 95% CI 0.01 to 7.58; RD ‐0.07, 95% CI ‐0.23 to 0.10; 1 study, 30 infants). No effect of indomethacin was demonstrated in the meta‐analysis (RR 0.33, 95% CI 0.01 to 7.58; RD ‐0.02, 95% CI ‐0.07 to 0.04; 2 studies, 119 infants; low‐certainty evidence; <a href="./references#CD013133-fig-0025" title="">Analysis 1.22</a>). </p> </section> </section> <section id="CD013133-sec-0098"> <h6 class="title">Platelet count (&lt; 50,000 platelets/µL blood)</h6> <p>This was not reported.</p> </section> <section id="CD013133-sec-0099"> <h6 class="title">Pulmonary hypertension (diagnosed by echocardiographic or Doppler criteria)</h6> <p>This was not reported.</p> </section> </section> </section> <section id="CD013133-sec-0100"> <h4 class="title">Indomethacin versus placebo or control (sensitivity analysis) (Comparison 2)</h4> <p>We conducted a sensitivity analysis for the primary outcomes excluding studies that were judged to have high risk of bias in one or more domains as specified a priori (<a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>). </p> <section id="CD013133-sec-0101"> <h5 class="title">Primary outcomes</h5> <section id="CD013133-sec-0102"> <h6 class="title">Failure of PDA closure within one week of administration of the first dose of indomethacin (Outcome 2.1) </h6> <p>Seven studies reported on PDA closure within one week of administration of the first dose of indomethacin in this analysis. Overall, indomethacin administration was associated with a large decrease in failure of PDA closure within one week of administration of the first dose of indomethacin (typical RR 0.29, 95% CI 0.22 to 0.38; typical RD ‐0.51, 95% CI ‐0.58 to ‐0.44; 7 studies, 586 infants; <a href="./references#CD013133-fig-0026" title="">Analysis 2.1</a>). This was seen in both studies that utilized enteral (typical RR 0.35, 95% CI 0.23 to 0.54; typical RD ‐0.49, 95% CI ‐0.64 to ‐0.35; 5 studies, 126 infants) or parenteral administration of indomethacin (typical RR 0.27, 95% CI 0.19 to 0.37; typical RD ‐0.52, 95% CI ‐0.60 to ‐0.44; 2 studies, 460 infants). </p> </section> <section id="CD013133-sec-0103"> <h6 class="title">Bronchopulmonary dysplasia (defined as supplemental oxygen need at 28 days' postnatal age with or without compatible clinical and radiographic findings) (Outcome 2.2) </h6> <p>Only one study reported on supplemental oxygen need at 28 days' postnatal age with or without compatible clinical and radiographic findings (parenteral administration: <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). In that small study, no impact on the risk of requiring supplemental oxygen at 28 days' postnatal age was reported (RR 1.45, 95% CI 0.60 to 3.51; 1 study, 55 infants; low‐certainty evidence; <a href="./references#CD013133-fig-0027" title="">Analysis 2.2</a>). </p> </section> <section id="CD013133-sec-0104"> <h6 class="title">Bronchopulmonary dysplasia (defined as supplemental oxygen at 36 weeks' postmenstrual age with or without compatible clinical and radiographic findings) (Outcome 2.3) </h6> <p>Only one study reported on supplemental oxygen need at 36 weeks' postmenstrual age with or without compatible clinical and radiographic findings (parenteral administration: <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>). In that study, no impact on the risk of requiring supplemental oxygen at 36 weeks' postmenstrual age was reported (RR 0.80, 95% CI 0.41 to 1.55; 1 study, 92 infants; low‐certainty evidence; <a href="./references#CD013133-fig-0028" title="">Analysis 2.3</a>). </p> </section> <section id="CD013133-sec-0105"> <h6 class="title">All‐cause neonatal mortality before hospital discharge (Outcome 2.4)</h6> <p>Five studies reported on all‐cause neonatal mortality before hospital discharge in this analysis. None of the individual studies reported an impact on all‐cause neonatal mortality before hospital discharge, and no effect of either parenteral or enteral indomethacin was demonstrated in the meta‐analysis (all studies typical RR 0.73, 95% CI 0.39 to 1.34; 5 studies, 239 infants; parenteral administration typical RR 1.02, 95% CI 0.45 to 2.29; 2 studies, 147 infants; enteral administration typical RR 0.46, 95% CI 0.17 to 1.22; 3 studies, 92 infants; <a href="./references#CD013133-fig-0029" title="">Analysis 2.4</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013133-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013133-sec-0106"></div> <section id="CD013133-sec-0107"> <h3 class="title" id="CD013133-sec-0107">Summary of main results</h3> <p>Fourteen studies completed to date have compared indomethacin to placebo or to no treatment. A total of 880 infants have been enrolled in these studies. Nine of the 14 studies compared intravenous indomethacin to placebo or no treatment (<a href="./references#CD013133-bbs2-0001" title="CottonRB , HickeyDE , GrahamTP , StahlmanMT . Effect of early indomethacin (I) on ventilatory status of preterm infants with symptomatic patent ductus arteriosus (sPDA). Pediatric Research1980;14:442. ">Cotton 1980</a>; <a href="./references#CD013133-bbs2-0002" title="GersonyWM , PeckhamGJ , EllisonRC , MiettinenOS , NadasAS . Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. Journal of Pediatrics1983;102(6):895-906. [DOI: 10.1016/s0022-3476(83)80022-5] [PMID: 6343572]PeckhamGJ , MiettinenOS , EllisonRC , KraybillEN , GersonyWM , ZierlerS , et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. Journal of Pediatrics1984;105(2):285-91. [DOI: 10.1016/s0022-3476(84)80134-1] [PMID: 6379136]">Gersony 1983</a>; <a href="./references#CD013133-bbs2-0003" title="KluckowM , EvansN , GillA , JefferyM . Ductal echocardiographic targeting and early closure trial (DETECT): a pilot randomised controlled trial. In: Journal of Paediatrics and Child Health. Vol. 48. 2012:43-4. KluckowM , JefferyM , GillA , EvansN . A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2014;99(2):F99–F104. [DOI: 10.1136/archdischild-2013-304695] [PMID: 24317704]VargheseJ , GillA , McMichaelJ , EvansNJ , RiegerI , BowenJ , et al. Follow up at 2 years of an early ductal targeted treatment (DETECT) trial. Journal of Paediatrics and Child Health2016;52(Suppl 2):102. ">Kluckow 2014</a>; <a href="./references#CD013133-bbs2-0004" title="KnightD , AlkindiS , BukshM , KuschelC , SkinnerJ . Placebo-controlled pilot trial of indomethacin in preterm infants with a patent ductus arteriosus. Journal of Paediatrics and Child Health2011;47:88. ">Knight 2011</a>; <a href="./references#CD013133-bbs2-0005" title="KraussAN , FaticaN , LewisBS , CooperR , ThalerHT , CirrincioneC , et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. American Journal of Diseases of Children1989;143(1):78–81. [DOI: 10.1001/archpedi.1989.02150130088021] [PMID: 2910050]">Krauss 1989</a>; <a href="./references#CD013133-bbs2-0006" title="MerrittTA , HarrisJP , RoghmannK , WoodB , CampanellaV , AlexsonC , et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. Journal of Pediatrics1981;99(2):281-6. [DOI: 10.1016/s0022-3476(81)80479-9] [PMID: 7019406]">Merritt 1981</a>; <a href="./references#CD013133-bbs2-0007" title="Monset-CouchardM , Dias-MançanoD , MuratI , RelierJP . [Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants]. Pediatrie1983;38(6):365-77. [PMID: 6364030]">Monset‐Couchard 1983</a>; <a href="./references#CD013133-bbs2-0010" title="OsbornDA , EvansN , KluckowM . Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Archives of Disease in Childhood: Fetal &amp; Neonatal Edition2003;88(6):F477-82. [DOI: 10.1136/fn.88.6.f477] [PMID: 14602694]">Osborn 2003</a>; <a href="./references#CD013133-bbs2-0014" title="BetkerurMV , YehTF , MillerK , GlasserRJ , PildesRS . Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics1981;68(1):99-102. [PMID: 6909683]YehTF , GoldbargHR , HenekT , ThaljiA , PildesRS . Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one year follow‐up. American Journal of Diseases of Children1982;136(9):803‐7. [DOI: 10.1001/archpedi.1982.03970450045012] [PMID: 7114004]YehTF , LukenJA , ThaljiA , RavalD , CarrI , PildesRS . Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus ‐ a double blind controlled study. Journal of Pediatrics1981;98(1):137-45. [DOI: 10.1016/s0022-3476(81)80560-4] [PMID: 7005415]YehTF , RavalD , LilienLD , SrinivasanG , PildesRS . Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. Pediatric Pharmacology (New York)1982;2(3):171-7. [PMID: 6761637]YehTF , RavalD , PyatiS , PildesRS . Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins1983;25(3):385-91. [DOI: 10.1016/0090-6980(83)90041-2] [PMID: 6346399]YehTF , ThaljiA , LukenL , LilienL , CarrI , PildesRS . Improved lung compliance following indomethacin therapy in premature infants with patent ductus arteriosus. Chest1981;80(6):698-700. [DOI: 10.1378/chest.80.6.698] [PMID: 7307591]">Yeh 1981a</a>). Five studies compared oral indomethacin to placebo or no treatment (<a href="./references#CD013133-bbs2-0008" title="NestrudRM , HillDE , ArringtonRW , BeardAG , DunganWT , LauPY , et al. Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics1980;1(2-3):125-36. [PMID: 6765467]">Nestrud 1980</a>; <a href="./references#CD013133-bbs2-0009" title="NeuJ , AriagnoRL , JohnsonJD , PitlickPT , CohenRS , BeetsCL , et al. A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management. Pediatric Pharmacology (New York)1981;1(3):245-9. [PMID: 7346744]">Neu 1981</a>; <a href="./references#CD013133-bbs2-0011" title="RuddP , MontanezP , Hallidie-SmithK , SilvermanM . Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Archives of Disease in Childhood1983;58(4):267-70. [DOI: 10.1136/adc.58.4.267] [PMID: 6342542]">Rudd 1983</a>; <a href="./references#CD013133-bbs2-0012" title="ValaesT , MoylanFM , CohnH , ChungK , NagpaulK , ChrenoffHL , et al. Incidence and significance of PDA in preterm infants (PTI) and controlled blind trial of indomethacin (IND). Pediatric Research1980;14:452. ">Valaes 1980</a>; <a href="./references#CD013133-bbs2-0013" title="YanagiRM , WilsonA , NewfeldEA , AzizKU , HuntCE . Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics1981;67(5):647-52. [PMID: 7019841]">Yanagi 1981</a>). </p> <p>Indomethacin appears to be significantly more effective than placebo or no treatment for patent ductus arteriosus (PDA) closure in preterm infants (high‐certainty evidence). Indomethacin use is also associated with a significantly reduced need for rescue medical treatment for PDA. The effectiveness of both intravenous and oral administration of indomethacin appears to be similar when compared to placebo or no treatment. There were no differences in the rates of other clinical outcomes nor in adverse effects. </p> </section> <section id="CD013133-sec-0108"> <h3 class="title" id="CD013133-sec-0108">Overall completeness and applicability of evidence</h3> <p>We recommend cautious interpretation and application of these findings. Although it was clearly demonstrated that indomethacin administration, as intravenous or oral formulation, was superior to placebo or no treatment in closing a PDA, evidence is insufficient to allow inferences on the clinical implications of this finding. No statistically significant differences could be demonstrated in rate of surgical PDA ligation, duration of assisted ventilation, bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP), or mortality. However, several limitations of the included studies prevent us from drawing firm conclusions on the lack of efficacy of indomethacin for clinical outcomes. First, imprecise effect estimates, as evident from their wide confidence intervals, for the above‐mentioned clinical outcomes fail to provide convincing evidence for absence of effect on these outcomes. Second, a significantly higher proportion of infants in the placebo or no treatment group ended up receiving open‐label medical therapy, thereby likely pulling the effect estimates for clinical outcomes towards null. The latter, especially, might be an important reason why significantly improved rates of PDA closure did not translate into lower rates of PDA ligation or longer‐term clinical benefit; this might need to be addressed in future trials. </p> <p>Evidence was insufficient to confidently establish the safety of indomethacin. No differences were demonstrated with respect to intestinal perforation, NEC, mucocutaneous or gastrointestinal bleeding, and transient renal impairment. However, imprecise effect estimates again fail to provide convincing evidence for safety with respect to these outcomes. Clinicians should consider this uncertainty of evidence on safety while considering indomethacin treatment for preterm infants. </p> <p>Clinicians should also consider the applicability of this evidence in the current clinical context. Eleven out of the 14 included studies were published before 1990, when neonatal clinical practices were vastly different, such as infrequent use of antenatal corticosteroids, lesser use of non‐invasive ventilatory support, and no availability of surfactant therapy. Therefore, clinicians should exercise caution when applying these results in the current context, especially with regards to extremely low gestational age infants at the limits of viability. </p> </section> <section id="CD013133-sec-0109"> <h3 class="title" id="CD013133-sec-0109">Quality of the evidence</h3> <p>Certainty of evidence for the primary outcome, failure of PDA closure, was high according to GRADE. Evidence for other clinical outcomes was of low to moderate certainty. Certainty of evidence should be considered in light of the fact that most included trials were conducted in the pretrial registration era, and publications were not mandated to follow CONSORT guidelines when reporting a clinical trial (<a href="./references#CD013133-bbs2-0063" title="MoherD . CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated standards of reporting trials. JAMA1998;279:1489-91. [DOI: 10.1001/jama.279.18.1489] [PMID: 9600488]">Moher 1998</a>). Therefore, risk of bias was unclear for several domains across trials. Furthermore, most trials were small‐sample pilot trials with insufficient power to detect statistically significant differences in rates of clinically relevant outcomes, thereby leading to serious or very serious imprecision on GRADE assessment. Despite the above limitations, certainty of evidence for ‘failure of PDA closure’ was high, as most of the evidence for this outcome was contributed by studies with low risk of bias with minimal inconsistency and precise effect estimates. </p> </section> <section id="CD013133-sec-0110"> <h3 class="title" id="CD013133-sec-0110">Potential biases in the review process</h3> <p>We are not aware of any biases in the review process. Departures from the protocol were primarily related to clarification of inclusion criteria and relevant outcomes. Review authors were not involved with any of the included trials. </p> </section> <section id="CD013133-sec-0111"> <h3 class="title" id="CD013133-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>The result for the primary outcome of ‘failure of PDA closure’ is consistent with the two existing network meta‐analyses comparing pharmacotherapeutic options for treatment of a symptomatic PDA (<a href="./references#CD013133-bbs2-0056" title="JonesLJ , CravenPD , AttiaJ , ThakkinstianA , WrightI . Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Archives of Disease in Childhood. Fetal &amp; Neonatal Edition2011;96(1):F45-52. [DOI: 10.1136/adc.2009.168682] [PMID: 20876595]">Jones 2011</a>; <a href="./references#CD013133-bbs2-0061" title="MitraS , FlorezID , TamayoME , MbuagbawL , VanniyasingamT , Angeliki VeronikiA , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA2018;319(12):1221-38. [DOI: 10.1001/jama.2018.1896] [PMID: 29584842]">Mitra 2018</a>). <a href="./references#CD013133-bbs2-0061" title="MitraS , FlorezID , TamayoME , MbuagbawL , VanniyasingamT , Angeliki VeronikiA , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA2018;319(12):1221-38. [DOI: 10.1001/jama.2018.1896] [PMID: 29584842]">Mitra 2018</a> showed that both intravenous indomethacin (network odds ratio (OR) 0.15, 95% credible interval (CrI) 0.09 to 0.22) and ‘indomethacin, other types’, which included oral indomethacin (network OR 0.15, 95% CrI 0.09 to 0.24), were associated with significantly lower rates of failure of PDA closure compared to placebo or no treatment. The earlier network meta‐analysis by <a href="./references#CD013133-bbs2-0056" title="JonesLJ , CravenPD , AttiaJ , ThakkinstianA , WrightI . Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Archives of Disease in Childhood. Fetal &amp; Neonatal Edition2011;96(1):F45-52. [DOI: 10.1136/adc.2009.168682] [PMID: 20876595]">Jones 2011</a> also shows that intravenous indomethacin was associated with significantly lower rates of failure of PDA closure compared to placebo (pooled risk ratio (RR) 0.42, 95% confidence interval (CI) 0.36 to 0.49). </p> <p>Although the network meta‐analysis by <a href="./references#CD013133-bbs2-0056" title="JonesLJ , CravenPD , AttiaJ , ThakkinstianA , WrightI . Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Archives of Disease in Childhood. Fetal &amp; Neonatal Edition2011;96(1):F45-52. [DOI: 10.1136/adc.2009.168682] [PMID: 20876595]">Jones 2011</a> did not show any statistically significant differences in other clinical outcomes, in keeping with the results of this review some differences were noted in the results of the network meta‐analysis by <a href="./references#CD013133-bbs2-0061" title="MitraS , FlorezID , TamayoME , MbuagbawL , VanniyasingamT , Angeliki VeronikiA , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA2018;319(12):1221-38. [DOI: 10.1001/jama.2018.1896] [PMID: 29584842]">Mitra 2018</a>. Mitra and colleagues demonstrated that the need for surgical PDA ligation was significantly lower with both intravenous indomethacin (network OR 0.29, 95% CrI 0.12 to 0.65) and ‘indomethacin, other types’ (network OR 0.25, 95% CrI 0.11 to 0.57) compared to placebo or no treatment (<a href="./references#CD013133-bbs2-0061" title="MitraS , FlorezID , TamayoME , MbuagbawL , VanniyasingamT , Angeliki VeronikiA , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA2018;319(12):1221-38. [DOI: 10.1001/jama.2018.1896] [PMID: 29584842]">Mitra 2018</a>). Furthermore, it was noted in <a href="./references#CD013133-bbs2-0061" title="MitraS , FlorezID , TamayoME , MbuagbawL , VanniyasingamT , Angeliki VeronikiA , et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA2018;319(12):1221-38. [DOI: 10.1001/jama.2018.1896] [PMID: 29584842]">Mitra 2018</a> that the risk of NEC was significantly higher with ‘indomethacin, other types’ (network OR 2.58, 95% CrI 1.06 to 6.65) compared to placebo or no treatment. No such differences were noted in our results. Differences in statistical analytical techniques might contribute to such differences in results. In our analyses, we used fixed‐effect meta‐analysis of direct comparisons only. Conversely, network meta‐analysis uses both direct and indirect comparisons to obtain network effect estimates. </p> <p>It is important to note key differences between our results and those of the previously published Cochrane Review on prophylactic intravenous indomethacin in preterm infants (<a href="./references#CD013133-bbs2-0043" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. Art. No: CD000174. [DOI: 10.1002/14651858.CD000174.pub2]">Fowlie 2010</a>). Although prophylactic intravenous indomethacin was shown to significantly reduce PDA surgical ligation (typical RR 0.51, 95% CI 0.37 to 0.71) and severe intraventricular hemorrhage (typical RR 0.66, 95% CI 0.53 to 0.82) (<a href="./references#CD013133-bbs2-0043" title="FowliePW , DavisPG , McGuireW . Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 7. Art. No: CD000174. [DOI: 10.1002/14651858.CD000174.pub2]">Fowlie 2010</a>), we were unable to demonstrate in our review such findings with use of indomethacin for symptomatic PDA. Such differences could largely be attributed to differences in methodological quality of included studies in the two respective reviews. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013133-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013133-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013133-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Indomethacin vs placebo or control, outcome: 1.1 Failure of PDA closure within 1 week of administration of the first dose of indomethacin." data-id="CD013133-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Indomethacin vs placebo or control, outcome: 1.1 Failure of PDA closure within 1 week of administration of the first dose of indomethacin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 1: Failure of PDA closure within 1 week of administration of the first dose of indomethacin" data-id="CD013133-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 1: Failure of PDA closure within 1 week of administration of the first dose of indomethacin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 2: Bronchopulmonary dysplasia at 28 days" data-id="CD013133-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 2: Bronchopulmonary dysplasia at 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 3: Bronchopulmonary dysplasia at 36 weeks' gestation" data-id="CD013133-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 3: Bronchopulmonary dysplasia at 36 weeks' gestation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 4: All‐cause neonatal mortality before hospital discharge" data-id="CD013133-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 4: All‐cause neonatal mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 5: Proportion of infants receiving rescue medical treatment" data-id="CD013133-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 5: Proportion of infants receiving rescue medical treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 6: Proportion of infants requiring surgical ligation of PDA" data-id="CD013133-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 6: Proportion of infants requiring surgical ligation of PDA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 7: Pulmonary hemorrhage" data-id="CD013133-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 7: Pulmonary hemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 8: Late‐onset bacterial sepsis" data-id="CD013133-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 8: Late‐onset bacterial sepsis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 9: NEC (≥ Bell stage 2)" data-id="CD013133-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 9: NEC (≥ Bell stage 2)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 10: IVH (any grade)" data-id="CD013133-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 10: IVH (any grade)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 11: Severe IVH (grade III to IV)" data-id="CD013133-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 11: Severe IVH (grade III to IV) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 12: Periventricular leukomalacia" data-id="CD013133-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 12: Periventricular leukomalacia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 13: Retinopathy of prematurity (any stage)" data-id="CD013133-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 13: Retinopathy of prematurity (any stage) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 14: Severe retinopathy of prematurity (≥ stage III)" data-id="CD013133-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 14: Severe retinopathy of prematurity (≥ stage III) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 15: Surgery for severe retinopathy of prematurity*" data-id="CD013133-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 15: Surgery for severe retinopathy of prematurity* </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 16: Infant mortality (first year of life)" data-id="CD013133-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 16: Infant mortality (first year of life) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 17: Use of inotropic agents" data-id="CD013133-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 17: Use of inotropic agents</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 18: Duration of assisted ventilation (days)" data-id="CD013133-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 18: Duration of assisted ventilation (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 19: Duration of hospital stay (days)" data-id="CD013133-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 19: Duration of hospital stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 20: Intestinal perforation" data-id="CD013133-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 20: Intestinal perforation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 21: Creatinine &gt; 150 micromole during treatment" data-id="CD013133-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 21: Creatinine &gt; 150 micromole during treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Indomethacin vs placebo or control, Outcome 22: Mucocutaneous or gastrointestinal bleeding" data-id="CD013133-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Indomethacin vs placebo or control, Outcome 22: Mucocutaneous or gastrointestinal bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Indomethacin vs placebo or control (sensitivity analysis), Outcome 1: Failure of PDA closure within 1 week of administration of the first dose of indomethacin" data-id="CD013133-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Indomethacin vs placebo or control (sensitivity analysis), Outcome 1: Failure of PDA closure within 1 week of administration of the first dose of indomethacin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Indomethacin vs placebo or control (sensitivity analysis), Outcome 2: Bronchopulmonary dysplasia at 28 days" data-id="CD013133-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Indomethacin vs placebo or control (sensitivity analysis), Outcome 2: Bronchopulmonary dysplasia at 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Indomethacin vs placebo or control (sensitivity analysis), Outcome 3: Bronchopulmonary dysplasia at 36 weeks' gestation" data-id="CD013133-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Indomethacin vs placebo or control (sensitivity analysis), Outcome 3: Bronchopulmonary dysplasia at 36 weeks' gestation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013133-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/urn:x-wiley:14651858:media:CD013133:CD013133-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Indomethacin vs placebo or control (sensitivity analysis), Outcome 4: All‐cause neonatal mortality before hospital discharge" data-id="CD013133-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_t/tCD013133-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Indomethacin vs placebo or control (sensitivity analysis), Outcome 4: All‐cause neonatal mortality before hospital discharge </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/media/CDSR/CD013133/image_n/nCD013133-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013133-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Indomethacin compared to placebo or control for symptomatic patent ductus arteriosus in preterm infants</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Indomethacin compared to placebo or control for symptomatic patent ductus arteriosus in preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> symptomatic patent ductus arteriosus in preterm infants<br/><b>Setting:</b> neonatal intensive care setting<br/><b>Intervention:</b> indomethacin<br/><b>Comparison:</b> placebo or control </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with indomethacin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Failure of PDA closure within 1 week of administration of the first dose of indomethacin</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.30<br/>(0.23 to 0.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>654<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>732 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000<br/>(168 to 278) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bronchopulmonary dysplasia at 28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/>(0.60 to 3.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>55<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>322 per 1000<br/>(133 to 780) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bronchopulmonary dysplasia at 36 weeks' gestation</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.41 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000<br/>(128 to 484) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause neonatal mortality before hospital discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.46 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>314<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000<br/>(75 to 217) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Proportion of infants requiring surgical ligation of PDA</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.33 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>275<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000<br/>(37 to 146) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NEC (≥ Bell stage 2)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/>(0.36 to 4.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>147<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(19 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mucocutaneous or gastrointestinal bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33</p> <p>(0.01 to 7.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>119<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; NEC: necrotizing enterocolitis; OR: odds ratio; PDA: patent ductus arteriosus; RCT: randomized controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision (there are few events in a small sample single RCT, and the CI includes appreciable benefit and harm). </p> <p><sup>b</sup>Downgraded one level for serious imprecision (the CI includes appreciable benefit and harm). </p> <p><sup>c</sup>Downgraded two levels for very serious imprecision (there are few events from two small sample RCTs, and the CI includes appreciable benefit and harm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Indomethacin compared to placebo or control for symptomatic patent ductus arteriosus in preterm infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/full#CD013133-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013133-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Indomethacin vs placebo or control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Failure of PDA closure within 1 week of administration of the first dose of indomethacin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.23, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.21, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Enteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.23, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Bronchopulmonary dysplasia at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.60, 3.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.60, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Bronchopulmonary dysplasia at 36 weeks' gestation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause neonatal mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.46, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.52, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Enteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.17, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Proportion of infants receiving rescue medical treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.23, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.24, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Enteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.06, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Proportion of infants requiring surgical ligation of PDA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.33, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.19, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Enteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.37, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Pulmonary hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.14, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.14, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Late‐onset bacterial sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.46, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.48, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Enteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 6.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 NEC (≥ Bell stage 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.36, 4.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.36, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 IVH (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.20, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.20, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Severe IVH (grade III to IV) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Periventricular leukomalacia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.29, 4.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.29, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Retinopathy of prematurity (any stage) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.07, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.07, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Severe retinopathy of prematurity (≥ stage III) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 14.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 14.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Surgery for severe retinopathy of prematurity* <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Infant mortality (first year of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.49, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.49, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Use of inotropic agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.50, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.50, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Duration of assisted ventilation (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐3.55, 4.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐3.55, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Duration of hospital stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.30 [‐51.36, 22.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.30 [‐51.36, 22.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Intestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Creatinine &gt; 150 micromole during treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.07, 16.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.21.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.07, 16.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Mucocutaneous or gastrointestinal bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.22.2 Enteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Indomethacin vs placebo or control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013133-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Indomethacin vs placebo or control (sensitivity analysis)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Failure of PDA closure within 1 week of administration of the first dose of indomethacin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.22, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.19, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Enteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.23, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Bronchopulmonary dysplasia at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.60, 3.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.60, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Bronchopulmonary dysplasia at 36 weeks' gestation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 All‐cause neonatal mortality before hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.39, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Parenteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.45, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Enteral administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.17, 1.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Indomethacin vs placebo or control (sensitivity analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013133.pub2/references#CD013133-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013133.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013133-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013133-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013133-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013133-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013133-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013133-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013133-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD013133-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013133-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013133-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013133\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013133\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013133\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013133\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013133\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=u3GUW7vS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013133.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013133.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013133.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013133.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013133.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716728896"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013133.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716728900"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013133.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da69c8bf89368',t:'MTc0MDcxNjcyOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 